

# Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter

John L. Wallace<sup>1,2</sup> and Rui Wang<sup>3</sup>

Abstract | Hydrogen sulfide (H<sub>2</sub>S) has become recognized as an important signalling molecule throughout the body, contributing to many physiological and pathological processes. In recent years, improved methods for measuring H<sub>2</sub>S levels and the availability of a wider range of H<sub>2</sub>S donors and more selective inhibitors of H<sub>2</sub>S synthesis have helped to more accurately identify the many biological effects of this highly reactive gaseous mediator. Animal studies of several H<sub>2</sub>S-releasing drugs have demonstrated considerable promise for the safe treatment of a wide range of disorders. Several such drugs are now in clinical trials.

**Cystathionine  $\gamma$ -lyase (CSE).** An enzyme that converts L-cysteine into hydrogen sulfide, pyruvate and ammonia. It requires the cofactor pyridoxal phosphate (vitamin B6) for this activity.

**Cystathionine  $\beta$ -synthase (CBS).** An enzyme that catalyses the conversion of homocysteine to cystathionine (the first step in the trans-sulfuration pathway) and the condensation of homocysteine and cysteine to form cystathionine and hydrogen sulfide.

<sup>1</sup>Department of Physiology & Pharmacology, University of Calgary, Calgary, Alberta T2N 4N1, Canada.

<sup>2</sup>Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario M5S 2J7, Canada.

<sup>3</sup>Department of Biology, Lakehead University, Thunder Bay, Ontario P7B5E1, Canada.  
Correspondence to J.L.W.  
e-mail: [altapharm@hotmail.com](mailto:altapharm@hotmail.com)  
doi:10.1038/nrd4433  
Published online 7 April 2015

Over the past 15 years, hydrogen sulfide (H<sub>2</sub>S) has become recognized as a crucial signalling molecule with a wide range of physiological functions<sup>1,2</sup>. It can profoundly affect most organ systems in animals and humans, but it also contributes to many functions in plants and prokaryotes. Indeed, H<sub>2</sub>S had important roles in the development of life on Earth during the 500 million years before photosynthesis<sup>3</sup>. The realization of the biological importance of H<sub>2</sub>S in numerous cells, tissues and organs is now shedding light on the pathogenesis of various human diseases, and paving the way for innovative therapeutic interventions.

In this article, we review the pathways for the synthesis and metabolism of H<sub>2</sub>S (FIG. 1), its major mechanisms of action, and some of the key disease processes in which H<sub>2</sub>S appears to participate, as well as the tissues affected. Methods for measuring H<sub>2</sub>S levels *in vivo*, which are crucial for the study of H<sub>2</sub>S biology, are discussed in BOX 1. Also discussed are the concerns associated with the reliability and accuracy of such measurements, which have triggered debate on the physiologically relevant endogenous levels of H<sub>2</sub>S and the use of H<sub>2</sub>S donors in high micromolar concentrations to mimic the physiological actions of H<sub>2</sub>S. Finally, we provide examples of attempts to exploit the actions of H<sub>2</sub>S in the design of novel therapeutic agents for the treatment of arthritis, inflammatory bowel disease, myocardial dysfunction and chemoprevention of cancer.

## H<sub>2</sub>S synthesis and metabolism

**H<sub>2</sub>S synthesis.** H<sub>2</sub>S is produced in mammalian cells mostly through the reverse trans-sulfuration pathway (FIG. 1). Two pyridoxal 5'-phosphate (PLP)-dependent enzymes — cystathionine  $\gamma$ -lyase (CSE) and cystathionine

$\beta$ -synthase (CBS) — catalyse the production of H<sub>2</sub>S, ammonia and pyruvate from L-cysteine and homocysteine, respectively. A PLP-binding domain is common to CSE and CBS, and is crucial for their catalytic activities. Unlike CSE, CBS contains a 70-amino-acid haem domain in its amino terminus, which equips CBS to perform three functions. First, it offers an interaction site for two other gasotransmitters: nitric oxide (NO) and carbon monoxide. Second, it can act as a redox sensor to regulate its own production of H<sub>2</sub>S (notably, without a haem domain, CBS is no longer reactive to oxidative stress)<sup>4</sup>. Third, it performs as an oxygen sensor for the regulation of CBS degradation: an increase in the partial pressure of oxygen leads to the oxygenation of the haem group such that the conformational change of CBS can be recognized by Lon protease, triggering its degradation of CBS<sup>5</sup>.

Like CSE and CBS, cysteine aminotransferase (CAT) uses PLP as a cofactor and converts cysteine to 3-mercaptopyruvate. Using zinc as a cofactor, 3-mercaptopyruvate sulfurtransferase (MST) transfers the sulfur in the sulfane group of 3-mercaptopyruvate to other sulfur acceptors. In essence, MST acts as a sulfur carrier, rather than an H<sub>2</sub>S producer, as the sequential reactions that are catalysed by CAT and MST generate sulfane sulfur. This bound sulfur has to be released or reduced to liberate H<sub>2</sub>S (REF. 6). Another sulfur-carrying enzyme in our bodies is rhodanese (also known as thiosulfate sulfurtransferase)<sup>7</sup>. However, the biological and physiological importance of this enzyme in endogenous H<sub>2</sub>S metabolism has not been fully determined. In contrast to MST, which is localized both in the cytosol and mitochondria, rhodanese is a true mitochondrial protein.

***H<sub>2</sub>S metabolism and excretion.*** Unlike NO, H<sub>2</sub>S is relatively stable in body fluids. In the circulation and in the cytoplasm, free H<sub>2</sub>S can be scavenged by methaemoglobin<sup>8</sup> or by metallo- or disulfide-containing macromolecules that function as sulfane-sulfur and bound-sulfate pools. Oxidation and methylation are another two mechanisms of H<sub>2</sub>S metabolism. H<sub>2</sub>S is oxidized sequentially in the mitochondrion to thio-sulfate and then to sulfite, with the end-product under physiological conditions being sulfate<sup>9</sup>. The mitochondrial enzyme sulfide-quinone reductase has a crucial role in the oxidation of H<sub>2</sub>S (REF. 10). The cytosol is the major intracellular site of H<sub>2</sub>S methylation. Thiol S-methyltransferase catalyses the methylation of H<sub>2</sub>S to yield methanethiol and dimethylsulfide.

H<sub>2</sub>S is excreted in urine and flatus as free sulfate, thiosulfate or free sulfide, and is also exhaled in breath<sup>11</sup>.

***Tissue-specific distribution and intracellular compartmentalization of H<sub>2</sub>S-generating enzymes.*** Among the mammalian tissues that express CSE are the cardiovascular system<sup>12,13</sup>, liver, kidney, uterus, placenta, pancreatic islets<sup>13,14</sup>, lung<sup>15</sup>, and gastrointestinal tract<sup>16–19</sup>. Previously, although CSE mRNA had been detected in the brain, the lack of CSE expression in the nervous system was taken for granted<sup>20</sup>. However, a recent study revealed abundant expression of CSE proteins in the mouse and human striatum, cortex, and cerebellum<sup>21</sup>.

The brain is the primary organ in which CBS expression is dominant. CBS protein has been identified in the hippocampus, cerebellum, cerebral cortex, and brainstem<sup>22,23</sup>. CBS expression and activities in other tissues, such as the liver, kidney, pancreas, gastrointestinal tract, and lungs, have been confirmed<sup>5,6,12,17,19,24–26</sup>. The expression of CBS protein in the cardiovascular system and the functional relevance of such expression have not been convincingly established. A recent study detected a CBS protein band in cardiac tissues<sup>27</sup>, although such expression had not been detected in many previous studies. The answer to the controversy may not be simple, but certainly the specificity of the antibody used, the real identify of the protein band detected in western-blot analysis, and the use of appropriate positive and negative controls should be considered. These considerations and cautions also apply to the detection of CSE protein<sup>28</sup> and MST protein in western-blot analyses.

MST is expressed in the central nervous system, — mostly in glial cells<sup>29</sup>, hippocampal pyramidal neurons, cerebellar Purkinje cells, and mitral cells in the olfactory bulb<sup>30</sup>. Both MST and CAT are detected in certain types of vascular endothelium. The expression of MST has also been detected in vascular smooth muscle cells<sup>31</sup>, cardiomyocytes<sup>29</sup>, kidney cells and liver cells<sup>29,32</sup>.

Under physiological conditions, CSE proteins are mainly localized in the cytosol<sup>33</sup>. Increases in intracellular free calcium levels in vascular smooth muscle cells, due either to the entry of extracellular calcium or to the release of intracellular calcium from the endoplasmic reticulum, trigger the translocation of CSE from the cytosol to the mitochondrion<sup>33</sup>. It should be noted that the endogenous substance or substances that elicit CSE

translocation to the mitochondrion have not yet been identified. It may also be possible that pathophysiological stimuli such as hypoxia directly increase intracellular calcium levels and result in the subsequent translocation of CSE. Interestingly, this mitochondrial translocation of CSE is not observed in hepatocytes<sup>5</sup>.

CBS has also been conventionally regarded as being compartmentalized to the cytosol. Recent studies in liver cells<sup>5</sup> and colon-cancer-derived epithelial cells<sup>26</sup> show the existence of CBS proteins in the mitochondrion under resting conditions. MST and CAT are located both in the cytosol and in mitochondria<sup>6,30</sup>.


Based on the tissue-specific expression patterns of various H<sub>2</sub>S-generating enzymes, one may estimate the major enzymatic sources of H<sub>2</sub>S in various organs and cells. H<sub>2</sub>S production in the cardiovascular system is predominantly regulated by CSE, whereas CBS is the enzyme mostly responsible for H<sub>2</sub>S production in the nervous system. In other systems and organs, multiple enzymes may control the production of H<sub>2</sub>S, and their individual contributions may vary depending on the developmental stage and any disturbance of homeostasis. However, the above estimation clearly oversimplifies the complex nature of endogenous H<sub>2</sub>S metabolism. For example, even within the central nervous system, different types of neurons or glial cells may rely on CSE or MST rather than CBS to produce H<sub>2</sub>S. Furthermore, the endogenous production of H<sub>2</sub>S depends on substrate availability and other properties of the intracellular milieu that may differentially affect enzyme activities, in addition to the expression and distribution of these enzymes.

### Cellular and molecular effects of H<sub>2</sub>S

H<sub>2</sub>S participates in the regulation of homeostasis of numerous systems in our body, including but not limited to the cardiovascular, neuronal, gastrointestinal, respiratory, renal, liver and reproductive systems. The lipid-soluble nature of H<sub>2</sub>S enables this gasotransmitter to easily reach its molecular targets — on the plasma membrane, inside the cytosol or in intracellular organelles. This ubiquitous membrane permeability underlies the wide scope of the physiological or biological effects of H<sub>2</sub>S, but it is its unique chemical reactivity with certain types of macromolecules in different types of cells that makes H<sub>2</sub>S a selective, specific and powerful signalling molecule.

***Interactions with ion channels.*** Numerous cellular effects of H<sub>2</sub>S are mediated by its interactions with membrane ion channels. The ATP-sensitive potassium (K<sub>ATP</sub>) channel was the first-identified molecular target of endogenous H<sub>2</sub>S, and it mediates H<sub>2</sub>S-induced vasorelaxation<sup>13</sup>. The activation of K<sub>ATP</sub> channels by H<sub>2</sub>S has been reported in cardiovascular<sup>13,34</sup>, endocrine<sup>35</sup>, respiratory<sup>36</sup>, nervous<sup>37,38</sup> and gastrointestinal systems<sup>39,40</sup>. It seems that multiple subunits of the K<sub>ATP</sub> channel complex are modified by H<sub>2</sub>S. Using a whole-cell patch-clamp technique and a mutagenesis approach, Jiang *et al.*<sup>41</sup> demonstrated that H<sub>2</sub>S specifically acts on the sulfonylurea receptor 1 (SUR1; also known as ABCC8) subunit of the K<sub>ATP</sub> channel complex to activate these channels. Specifically, the amino-acid targets

Cysteine aminotransferase (CAT). An enzyme that catalyses the conversion of L-cysteine and α-ketoglutarate to 3-mercaptopyruvate and glutamate. Another enzyme, 3-mercaptosulfurtransferase, can then catabolize the generation of hydrogen sulfide from 3-mercaptopyruvate.



**Figure 1 | Cytosolic and mitochondrial production and functions of H<sub>2</sub>S.** Depending on the cell type and specific stress conditions, endogenous hydrogen sulphide (H<sub>2</sub>S) production can occur in the cytosol and/or the mitochondria<sup>6</sup>. Cystathionine  $\gamma$ -lyase (CSE)-mediated H<sub>2</sub>S production usually occurs in the cytosol; however, under stress conditions CSE can be translocated from the cytosol into the mitochondrion, where it catalyses H<sub>2</sub>S production from cysteine (Cys). Cysteine aminotransferase (CAT) and 3-mercaptopyruvate sulfurtransferase (MST) are located both in the cytosol and mitochondria, and regulate H<sub>2</sub>S production. Cystathionine  $\beta$ -synthase (CBS) is located in the cytosol, but can also be found in the mitochondrion of certain cell types under resting conditions. Hypoxia decreases the degradation of CBS in the mitochondrion, leading to an accumulation of CBS and thus increasing production of H<sub>2</sub>S in this organelle. HCY, homocysteine; PDE, phosphodiesterase; pO<sub>2</sub>, partial pressure of oxygen.

of H<sub>2</sub>S are the Cys6 and Cys26 residues of the extracellular N terminus of the SUR1 subunit. The SUR2B subunit of K<sub>ATP</sub> channels in colonic circular smooth muscle cells is S-sulfhydrated by sodium hydrosulfide (NaHS); this action underlies the increased K<sub>ATP</sub> channel current that is induced by NaHS and blocked by the sulfonylurea drug glybenclamide<sup>42</sup>. Similarly, the pore-forming subunit of the K<sub>ATP</sub> channel (such as K<sub>ir</sub>6.1) in vascular smooth muscle cells can be S-sulfhydrated, leading to increased K<sub>ATP</sub> channel current amplitude and membrane hyperpolarization<sup>34,43</sup>.

Voltage-dependent calcium channels (VDCCs) are also important targets of H<sub>2</sub>S in various cell types. In isolated mouse pancreatic  $\beta$ -cells<sup>44</sup> and rat cardiomyocytes<sup>45</sup>, H<sub>2</sub>S inhibits L-type VDCC currents. The amplitude of the current through heterologously expressed recombinant voltage-gated calcium channel 3.2 (Ca<sub>v</sub>3.2)-subunit T-type VDCCs in HEK293 cells was also inhibited by

NaHS (at concentrations of 10  $\mu$ M–1 mM)<sup>46</sup>. Indirect evidence also showed that native T-type VDCCs in rat cardiomyoblasts (H9c2 cells) were inhibited by H<sub>2</sub>S, as Ni<sup>2+</sup> (which inhibits these channels) abolished NaHS-induced decreases in resting intracellular calcium concentration<sup>47</sup>. However, the effects of H<sub>2</sub>S on VDCCs appear to be tissue-specific; in neurons, the activities of Ca<sub>v</sub>3.2 T-type VDCCs and Ca<sub>v</sub>1.2 L-type VDCCs are enhanced by endogenous and/or exogenous H<sub>2</sub>S<sup>48,49</sup>.

An important advance in vascular physiology in recent years is the identification of H<sub>2</sub>S as an endothelium-derived hyperpolarizing factor (EDHF)<sup>48,49</sup>. H<sub>2</sub>S activates small- and intermediate-conductance calcium-activated potassium channels (SK<sub>Ca</sub> channels and IK<sub>Ca</sub> channels, respectively), and H<sub>2</sub>S-induced endothelium-dependent smooth muscle hyperpolarization and vasorelaxation of mouse mesenteric arteries are abolished by the co-application of charybdotoxin and

**Box 1 | Determination of endogenous H<sub>2</sub>S levels**

Determining endogenous hydrogen sulfide (H<sub>2</sub>S) levels in the circulation and in tissues and cells is important for characterizing H<sub>2</sub>S as a gasotransmitter. It is also needed for evaluating whether exogenous H<sub>2</sub>S donors mimic the physiological and biological effects of endogenous H<sub>2</sub>S. As has been systematically reviewed recently<sup>176</sup>, a wide range — from 0.1 μM to more than 300 μM — of circulating H<sub>2</sub>S levels has been reported under physiological conditions. This remarkable variation is largely attributable to the wide array of measurement methods that have been used, including the colorimetric methylene blue method, ion-selective or polarographic electrodes, gas chromatography with flame photometry and the monobromobimane assay. Often, the total reactive sulfur pool — which does not distinguish free H<sub>2</sub>S from acid-labile sulfide or bound sulfur (also known as sulfane-sulfur) — was measured. The extent of H<sub>2</sub>S oxidation and/or H<sub>2</sub>S scavenging in biological samples may also skew estimations of the true concentrations of H<sub>2</sub>S. For example, it was reported that plasma levels of H<sub>2</sub>S could not be reliably measured, as red blood cells avidly scavenge H<sub>2</sub>S and remove it from the circulation<sup>177</sup>.

These measurement pitfalls have been addressed through the use of more advanced techniques. By measuring the H<sub>2</sub>S in headspace gas from plasma samples, Shen *et al.*<sup>178</sup> showed that the human plasma sulfide level is around 3 μM. Using the monobromobimane method coupled with reverse-phase high-performance liquid chromatography, the same authors recorded free hydrogen sulfide levels of 0.2–0.8 μM and acid-labile sulfur levels of 1.8–3.8 μM in plasma from mice and from humans<sup>178</sup>. With a combined modified gas chromatography and mass spectrometry technique, H<sub>2</sub>S levels of 0.5–2.5 μM were measured in pig and mouse blood<sup>176</sup>. Thus, as a conservative estimate, plasma H<sub>2</sub>S levels in healthy humans or animals are in the higher nanomolar to lower micromolar range<sup>178–180</sup>. However, there is still no consensus on the physiological levels of H<sub>2</sub>S in blood, or on the most acceptable and reliable techniques for measuring H<sub>2</sub>S in biological samples.

With respect to determining the physiological importance of H<sub>2</sub>S, does it matter if the circulatory or tissue levels of endogenous H<sub>2</sub>S are in the nanomolar or micromolar range? It seems not. At nanomolar or even picomolar concentrations, numerous endogenous substances exert profound physiological effects in different systems. Indeed, in many cases, it is the relative change in endogenous H<sub>2</sub>S levels that is more important in determining the physiological and pathophysiological importance of this gasotransmitter. This notion is exemplified by reports of the development of hypertension<sup>94</sup>, atherosclerosis<sup>101</sup>, diabetes<sup>119</sup>, renal ischaemic damage<sup>180</sup>, colitis<sup>155</sup>, acute liver failure<sup>153,181</sup> and Huntington disease<sup>21</sup> owing to reduced gene expression or activity of cystathionine γ-lyase (CSE).

As far as the issue of free H<sub>2</sub>S versus total reactive sulfur is concerned, what is important is the indication and interpretation of the measured levels, not the methods themselves. Ideally, we should precisely and reliably detect changes in each and all components of the total sulfur pool. Given that free H<sub>2</sub>S, acid-labile sulfide, and sulfane-sulfur are interchangeable under different conditions, an understanding of the mechanisms underlying the changes in this total reactive sulfur pool, and the physiological effects of such changes, carry biological and therapeutic importance.

However, should variations in H<sub>2</sub>S levels be used as biomarkers for the purpose of diagnosis and prognosis of certain diseases, it becomes imperative to accurately measure the absolute concentrations of H<sub>2</sub>S in the circulation and in tissues. Furthermore, the development of H<sub>2</sub>S-based therapies will be facilitated by accurately monitoring H<sub>2</sub>S levels in the circulation and/or in the targeted organs and systems in order to determine the pharmacokinetics and pharmacodynamics of H<sub>2</sub>S donors as well as their efficacy and toxicity profiles.

apamin<sup>50</sup>. The co-application of these two compounds specifically blocks IK<sub>Ca</sub> channels and SK<sub>Ca</sub> channels, and, as such, should block the vasorelaxant effect of an EDHF. The molecular basis for the role of H<sub>2</sub>S as an EDHF is the post-translational modification of the targets of H<sub>2</sub>S. H<sub>2</sub>S can sulfhydrylate IK<sub>Ca</sub> channels in primary human aortic endothelial cells<sup>51</sup>. Furthermore, in vascular tissues the expression of SK<sub>Ca</sub> 2.3 channels but not IK<sub>Ca</sub> 3.1 channels was increased by H<sub>2</sub>S and decreased by a CSE inhibitor or by deletion of the gene encoding CSE<sup>50</sup>.

The inhibitory effects of H<sub>2</sub>S on the α-subunit of big-conductance calcium-activated potassium (BK<sub>Ca</sub>) channels in heterologously transfected HEK293 cells have been reported<sup>52</sup>. Likewise, H<sub>2</sub>S inhibited native BK<sub>Ca</sub> channels in type 1 glomus cells from the isolated mouse carotid body<sup>53</sup>. By sharp contrast, ~300 μM NaHS (an H<sub>2</sub>S donor) increased whole-cell BK<sub>Ca</sub> currents and enhanced single-channel BK<sub>Ca</sub> activity in rat pituitary tumour cells<sup>54</sup>. This stimulatory effect of NaHS (10 μM) on BK<sub>Ca</sub> channels was also observed in endothelial cells<sup>55</sup>. These differential effects may be attributable to specific subtypes of BK<sub>Ca</sub> channels in different types of cells and to the concentrations of H<sub>2</sub>S donors.

The interaction of H<sub>2</sub>S with ion channels is not restricted to K<sub>ATP</sub> and K<sub>Ca</sub> channels. Delayed-rectifier K<sup>+</sup> channels in mouse gastric-muscle cells can be inhibited by H<sub>2</sub>S (REF. 56), whereas 4-aminopyridine (4-AP)-sensitive K<sup>+</sup> channels in rat coronary artery smooth muscle cells can be activated by H<sub>2</sub>S<sup>57</sup>. H<sub>2</sub>S has also been reported to activate chloride channels, voltage-gated sodium Na<sub>v</sub>1.5 channels and the transient receptor potential cation channels TRPV1 and TRPA1 in different tissues<sup>58</sup>.

As the physiological level of endogenous H<sub>2</sub>S in the circulation or in various types of cells is unclear, many of the aforementioned studies, such as those describing the effects of H<sub>2</sub>S on BK<sub>Ca</sub> channels, cannot be used as evidence for a physiological role of H<sub>2</sub>S in the regulation of different ion channels. Indeed, establishing such a physiological role of H<sub>2</sub>S would require a comparison of the characteristics of ion channels in the presence and absence of endogenous H<sub>2</sub>S. This forethought should be taken into account in all other studies that use H<sub>2</sub>S donors to deduce the physiological actions of H<sub>2</sub>S. Moreover, ion channels are diversified in their amino-acid composition, voltage dependency, gating mechanisms,

**4-aminopyridine** (4-AP). One of three isomeric amines of pyridine, which is widely used as a research tool to characterize the subtypes of potassium channels.

ion selectivity and sensitivity to different endogenous signalling molecules. This diversity forms the basis of the variable responses of ion channels to H<sub>2</sub>S exposure.

**Interactions with classical second messengers.** Although H<sub>2</sub>S can directly act on its target proteins without the engagement of second messengers, this gasotransmitter also affects the levels of several known second messengers. Non-selective inhibition of phosphodiesterases (PDEs) by H<sub>2</sub>S leads to decreased degradation of cyclic GMP and cyclic AMP, thereby increasing net cGMP and cAMP levels<sup>59–61</sup>. For example, with regard to cAMP levels, it has been demonstrated that H<sub>2</sub>S inhibits the mitochondrial-matrix-localized PDE2A in isolated rat liver mitochondria — leading to increased cAMP levels — as well as inhibiting the recombinant PDE2A enzyme *in vitro*<sup>51</sup>. Conversely, H<sub>2</sub>S can inhibit adenylyl cyclase in the rat kidney<sup>62</sup>. Thus, the net effect of H<sub>2</sub>S on cAMP levels could be determined by assessing the balance between the inhibition of PDEs and the inhibition of adenylyl cyclase.

Intracellular free calcium is another second messenger for cellular signal transduction. Via its effects on plasma membrane ion channels and on intracellular calcium pools, H<sub>2</sub>S can increase intracellular calcium levels in vascular endothelial cells by stimulating calcium influx<sup>63</sup> or by releasing calcium from an ATP- and 4-chloro-3-ethylphenol (4-CEP)-sensitive intracellular pool<sup>64</sup>. The consequent elevation of intracellular calcium levels may activate many calcium-dependent signalling pathways and enzymes such that endothelial proliferation and function can be regulated. H<sub>2</sub>S decreases intracellular calcium levels in cardiomyocytes by inhibiting both L-type and T-type VDCCs, but it increases intracellular calcium release in the same cell preparation<sup>47</sup>. The functional consequence of this biphasic effect of H<sub>2</sub>S is not clear. H<sub>2</sub>S increases calcium sparks in smooth muscle cells of intact piglet cerebral arterioles<sup>65</sup> and mesenteric arteries<sup>55</sup>. Increased calcium sparks activate transient K<sub>Ca</sub> channels and smooth muscle hyperpolarization; eventually, global intracellular free calcium levels drop and vasodilation ensues<sup>65</sup>.

**Protein S-sulfhydration.** At the amino-acid level, NO and H<sub>2</sub>S both modify sulfhydryl groups of certain proteins, but often generate opposite effects<sup>66</sup>. NO covalently modifies free sulfhydryls (–SH) of the cysteine residues of these targeted proteins to form S-nitrosothiols. Such S-nitrosylated proteins usually have decreased functions. Low-molecular-weight thiols or cysteine residues of proteins can also be modified via S-sulfhydration, in which the –SH from a sulfhydryl donor is transferred to cysteine sulfhydryls, forming a covalent persulfide (–SSH) in the target protein<sup>51</sup>.

The mechanisms for H<sub>2</sub>S-induced protein S-sulfhydration are under debate. As the sulfur in H<sub>2</sub>S and in –SH groups is at its lowest oxidative state, H<sub>2</sub>S may not be able to directly interact with the –SH group of cysteine to form a persulfide, and the oxidation of cysteine and/or the production of polysulfides may be prerequisite for protein S-sulfhydration.

The abundance of S-sulfhydrated proteins *in vivo* has also been questioned. Whereas a previous study using the biotin-switch assay reported that 10–25% of liver proteins are S-sulfhydrated<sup>43</sup>, another study using a tag-switch method revealed a much lower abundance of protein S-sulfhydration<sup>67</sup>. The pH of the cellular environment, and the proximity of the target cysteine amino acids to the active centrum of the protein would affect the extent of protein S-sulfhydration. Therefore, special attention should be paid to the sample preparation, including the oxidative state and level of protonation of cysteine thiol groups, in order to more accurately determine the extent of protein S-sulfhydration.

S-sulfhydration can affect numerous proteins<sup>68</sup>. For example, Kelch-like ECH-associated protein 1 (KEAP1) is a negative regulator of the activity of nuclear factor erythroid 2-related factor 2 (NRF2). H<sub>2</sub>S-induced S-sulfhydration of KEAP1 at Cys151 facilitates the dissociation of KEAP1 from NRF2, thereby resulting in an enhancement of NRF2-mediated antioxidant responses<sup>14</sup>.

The post-translational modification of nuclear factor-κB (NF-κB) serves as an example of the difference in functional effects between S-nitrosylation and S-sulfhydration. NF-κB is a transcription factor that regulates the expression of many inflammation- and apoptosis-responsive genes. S-nitrosylation of the Cys38 residue of the p65 subunit of NF-κB inhibits the binding of NF-κB to the cytokine-responsive sites in the promoter of the gene that encodes inducible NO synthase, resulting in decreased expression of this enzyme<sup>69</sup>. S-sulfhydration of the same cysteine residue, however, enhances the binding of NF-κB to ribosomal protein S3, which increases the transcriptional activity of p65 in the nucleus. Consequently, cell apoptosis is greatly inhibited<sup>68</sup>.

For a signal transduction process to be regulated, both ‘turn-on’ and ‘turn-off’ mechanisms are required. For example, the removal of NO from S-nitrosylated proteins occurs through the de-nitrosylation process. S-nitrosoglutathione reductase (GSNOR), a de-nitrosylation enzyme, reduces the product of protein S-nitrosylation, GSNO, to glutathione hydroxysulfenamide<sup>70</sup>. Thioredoxin, another de-nitrosylation enzyme<sup>71</sup>, has two redox-active cysteine residues (in the sequence Cys-Gly-Pro-Cys) in its active site. Thioredoxin breaks the disulfide bonds of its target protein and then binds with the same protein; this activity accounts for its antioxidant function. By de-nitrosylating its substrates, thioredoxin can reverse the function of S-nitrosylated proteins. However, our knowledge of protein de-sulfhydration is very limited. Mitochondrial persulfide dioxygenase (ETHE1) has been shown to catalyse the conversion of glutathione persulfide (GSSH) to sulfite *in vitro*. This process has important implications for mitochondrial sulfur catabolism and redox balance<sup>72</sup>. However, the physiological substrate for ETHE1 is not known, although the persulfide bound in the active-site peptide of sulfide-quinone oxidoreductase might be one candidate. Moreover, little is known about the de-sulfhydration of S-sulfhydrated proteins in the cytosol or non-mitochondrial organelles. It is conceivable, however, that the S-sulfhydrated proteins may be de-sulfhydrated

#### Calcium sparks

Intracellular Ca<sup>2+</sup> release events that play an important role in excitation–contraction coupling.

#### Tag-switch method

A technique used to measure protein S-sulfhydration, whereby S-sulfhydrated residues are labelled to form thioether conjugates.

in the presence of excess reductants and, as such, the level of oxygen will be a factor in the de-sulphydration process.

**Role in redox balance.** Redox is the integration of reduction and oxidation processes, in which electrons are transferred between species. Redox balance reflects a dynamic state in which oxidant and antioxidant levels are balanced. Increased oxidative stress and/or decreased antioxidant capability under various pathological situations disrupt the redox balance and cause damage to molecules and cells. The protective, antioxidant actions of H<sub>2</sub>S have been well established, particularly with respect to the vasculature. In cultured vascular smooth muscle cells, oxidative stress that was induced by high levels of homocysteine or methylglyoxal was markedly reduced by NaHS at concentrations of 30–90 μM (REFS 73,74). Moreover, the accumulation of lipid peroxidation products (including lipid hydroperoxide, the main contributor to the cytotoxic effect both of oxidized low-density lipoprotein (LDL) and of lipid derived from atheroma) in human umbilical vein endothelial cells (HUVECs) was inhibited or prevented by NaHS at 1–20 μM; endothelial cytotoxicity mediated by hydrogen peroxide and oxidized LDL was similarly inhibited or prevented by NaHS at these concentrations<sup>75</sup>. Oxidative stress-mediated death of amyloid-β-treated microglial cells was also inhibited by NaHS at concentrations as low as 25 μM (REF. 76). Although the physiological relevance of the antioxidant effect of H<sub>2</sub>S at these concentrations is unclear, the therapeutic value of H<sub>2</sub>S donors in this regard is certainly apparent.

In addition to its reducing nature, H<sub>2</sub>S influences the oxidant–antioxidant balance. Expression of the antioxidant enzyme thioredoxin 1 in vascular endothelial cells is upregulated by H<sub>2</sub>S (REF. 77), whereas the expression of NAD(P)H oxidase, a key source of extra-mitochondrial oxidant species, is downregulated in osteoblastic cells that have been exposed to H<sub>2</sub>S (REF. 78). The production of glutathione (GSH), a strong scavenger of free radicals, is also enhanced by H<sub>2</sub>S. It was shown that incubation of cultured mouse embryonic fibroblasts with NaHS induces nuclear translocation of NRF2 by S-sulphydrating KEAP1 at Cys151. As such, there was an increase in the binding of NRF2 to the antioxidant-response element (ARE), and an increase in ARE-mediated transcription of the genes involved in GSH synthesis and maintenance. The consequent increase in GSH levels contributes to the protective effect of H<sub>2</sub>S against cellular senescence induced by oxidative stress<sup>14</sup>.

The mitochondrion is the primary source of oxygen-derived free radicals and the organelle that is most affected by oxidative stress. Oxidative stress suppresses mitochondrial electron transport and bioenergetics, but these effects can be reversed by exogenous H<sub>2</sub>S (REF. 79). It was recently reported that nanomolar concentrations of a novel mitochondrion-targeted H<sub>2</sub>S donor, AP39, inhibited oxidative damage in microvascular endothelial cells *in vitro*<sup>80</sup>. GYY4137, a non-mitochondrion-targeted, slow-releasing H<sub>2</sub>S donor, produced protective effects similar to those produced by AP39, but only at a 1,000-fold higher concentration than that of AP39 (REF. 81).

**Oxygen sensing and mitochondrial bioenergetics.** Changes in the oxygenation status of cells affect endogenous H<sub>2</sub>S levels in different ways. Under hypoxic conditions, the oxidation of H<sub>2</sub>S in mitochondria is decreased, leading to a net elevation of H<sub>2</sub>S levels. In vascular smooth muscle cells, hypoxia or calcium overloading also leads to the translocation of CSE from the cytosol to mitochondria, where CSE uses approximately three-fold higher concentrations of L-cysteine to produce H<sub>2</sub>S (REF. 33). In addition, whereas under normoxic conditions CBS in hepatocytes is degraded inside mitochondria by Lon protease<sup>5</sup>, upon hypoxic stress Lon protease cannot recognize the deoxygenated haem group in CBS, and therefore CBS is not degraded. The accumulation of CBS protein in the mitochondrion leads to increased mitochondrial production of H<sub>2</sub>S (REF. 5).

It appears that different tissues handle changes in the partial pressure of oxygen differently by altering their H<sub>2</sub>S production and oxidation, as well as by changing their responses to H<sub>2</sub>S. For example, H<sub>2</sub>S dilates systemic blood vessels<sup>82</sup> and/or promotes angiogenesis to increase blood supply to hypoxic tissues<sup>83</sup>. By contrast, in hypoxic rat lungs, H<sub>2</sub>S constricts vascular smooth muscle in order to achieve regional ventilation–perfusion matching, in a mechanism known as hypoxic pulmonary vasoconstriction<sup>84,85</sup>. In this way, H<sub>2</sub>S helps the diversion of blood from oxygen-deprived areas to oxygen-supplied areas<sup>86</sup>. At the same time, H<sub>2</sub>S dilates airway smooth muscle to increase lung ventilation (in humans)<sup>36</sup> and to reduce airway resistance (in mice)<sup>15</sup>. These compensatory changes induced by H<sub>2</sub>S in response to hypoxia help improve the efficiency of pulmonary gas exchange. Moreover, H<sub>2</sub>S mediates the response of carotid-body chemoreceptors to hypoxia by modulating BK<sub>Ca</sub> channels<sup>53</sup>. As far as bioenergy production is concerned, under hypoxic conditions the upregulated mitochondrial production of H<sub>2</sub>S — which can act as an electron donor in the mitochondrial respiratory chain — contributes to the generation of bioenergy<sup>79</sup>. Thus, in facing a hypoxic challenge, mitochondrial production of ATP can be maintained by hypoxia-increased H<sub>2</sub>S levels<sup>33,86,87</sup>.

It should be mentioned that the notion of an ‘oxygen sensor’ role of H<sub>2</sub>S does not go without challenge<sup>88</sup>. A decrease in the partial pressure of oxygen in pulmonary circulation does not always lead to an increase in H<sub>2</sub>S levels, and H<sub>2</sub>S does not always cause the constriction of pulmonary arteries. For instance, in hypoxic pulmonary hypertension, hypoxia and a reduction of H<sub>2</sub>S levels in the pulmonary circulation occur in parallel<sup>89</sup>. In another example, in contrast to the assumed vasoconstrictive effect of H<sub>2</sub>S on pulmonary arteries, one recent study showed that, under normoxic conditions, H<sub>2</sub>S actually dilated pre-constricted human lobar pulmonary artery rings and reduced pulmonary artery pressure<sup>90</sup>. It is not yet clear whether the vasoactive effects of H<sub>2</sub>S on pulmonary circulation, and the interaction of H<sub>2</sub>S with hypoxia, are species-specific.

### H<sub>2</sub>S in disease processes

H<sub>2</sub>S levels contribute to homeostasis of the organism, and abnormally increased or decreased endogenous H<sub>2</sub>S production is associated with various diseases. Among the most-studied diseases related to abnormal

H<sub>2</sub>S metabolism are those involving the cardiovascular, endocrine, gastrointestinal and nervous systems. For the pathological roles of H<sub>2</sub>S in other mammalian systems, readers are referred to other recent review articles<sup>2,5,91</sup>.

**Hypertension and vascular remodelling.** As an EDHF, H<sub>2</sub>S induces the relaxation of many systemic blood vessels. When it is produced in smooth muscle cells or other non-endothelial cells, H<sub>2</sub>S also dilates blood vessels by directly relaxing smooth muscle cells<sup>12,92</sup>. These endothelium-dependent and -independent vasorelaxant effects of H<sub>2</sub>S are linked to the role of H<sub>2</sub>S in blood pressure regulation. Since the early study by Zhao *et al.*<sup>93</sup> in rats that showed that pharmacological inhibition of CSE elevated blood pressure, the role of H<sub>2</sub>S in regulating blood pressure has become increasingly clear. Mice that are genetically deficient in CSE (CSE-knockout mice) exhibit an age-dependent development of hypertension that is largely due to diminished endothelial production of H<sub>2</sub>S and endothelium-dependent relaxation of peripheral resistance arteries<sup>82</sup>. Similarly to CSE-knockout mice, spontaneously hypertensive rats (SHRs) exhibit age-dependent development of hypertension that correlates with diminished CSE expression and H<sub>2</sub>S production in aortic tissues<sup>82,94</sup>. The treatment of CSE-knockout mice with NaHS at 3.9 μmol per kg, 19.5 μmol per kg, and 39 μmol per kg (intravenous administration) or of SHRs with NaHS at 56 μmol per kg (intraperitoneal (i.p.) administration) suppressed the development of hypertension, decreased vascular damage and prevented vascular remodelling<sup>82,94,95</sup>.

Altered H<sub>2</sub>S metabolism has been linked to pulmonary hypertension. After high pulmonary blood flow-induced pulmonary hypertension was established in rats after an abdominal aorta–inferior cava vein shunt operation, the plasma level of H<sub>2</sub>S and CSE mRNA levels in lung tissues were significantly lower than in normotensive control rats<sup>96</sup>. In another rat model of hypoxia-induced pulmonary hypertension, the animals were exposed to normobaric hypoxia (10% oxygen) in a transparent plastic hypoxia chamber for 3 weeks. In these hypertensive rats, H<sub>2</sub>S production and CSE expression in lung tissues decreased significantly compared with that in control rats<sup>89,97</sup>. In rats with hypoxic pulmonary hypertension, daily treatment with NaHS at 14 μmol per kg (i.p. administration) provided anti-hypertensive protection in these animals and reduced the extent of remodelling of pulmonary arteries<sup>89,97</sup>.

In the two-kidney-one-clip model of renovascular hypertension, upregulated renin expression and increased activity of plasma renin and angiotensin II are markers of the severity of the disorder. As reflected by these measures, systemic hypertension was either prevented or attenuated by daily administration of NaHS (at doses of 30–100 μmol per kg) to rats in this model<sup>62</sup>.

The role of H<sub>2</sub>S in gestational hypertension has also been investigated. Hypertension is one of the major characteristics of pre-eclampsia — a disorder that affects women during pregnancy, but that has no clear aetiology. Endogenous H<sub>2</sub>S is required for healthy placental vasculature, whereas decreased CSE or H<sub>2</sub>S activity may contribute to the pathogenesis of pre-eclampsia. In pregnant mice, the inhibition of CSE with propargylglycine

induced hypertension and promoted abnormal labyrinthine vascularization in the placenta<sup>98</sup>. Women with pre-eclampsia exhibit decreased plasma levels of H<sub>2</sub>S and reduced expression of CSE in the placenta compared with gestational, age-matched controls<sup>98</sup>, and the therapeutic value of H<sub>2</sub>S donors (NaHS or GYY4137) in pre-eclampsia has been shown in mice<sup>98</sup> and rats<sup>99</sup>.

**Angiogenesis and atherosclerosis.** H<sub>2</sub>S increases vascular endothelial cell proliferation and migration, microvessel formation and the healing of wounds and ulcers both *in vivo* and *in vitro*. These pro-angiogenic effects of H<sub>2</sub>S are proposed to be mediated through the phosphorylation of AKT, extracellular signal-regulated kinase (ERK) and p38, as well as through the activation of K<sub>ATP</sub> channels<sup>18,83,92,100</sup>. The interaction of vascular endothelial growth factor (VEGF) and H<sub>2</sub>S constitutes another important pro-angiogenesis mechanism. Rats treated with NaHS (50 μmol per kg, twice daily) showed increased free plasma levels of VEGF and upregulated renal expression of *Vegfa* mRNA. *In vitro* incubation of podocytes with NaHS resulted in VEGF release and upregulation of *Vegfa* mRNA levels<sup>99</sup>. In turn, VEGF stimulates the release of H<sub>2</sub>S from vascular endothelial cells<sup>83</sup>. Thus, H<sub>2</sub>S and VEGF individually and synergistically stimulate angiogenesis. Similarly, the interaction between H<sub>2</sub>S and NO can affect angiogenesis<sup>60,66,100</sup>. NaHS was shown to promote the phosphorylation of endothelial NO synthase in cultured HUVECs, leading to increased production of NO, which further contributed to endothelial cell proliferation and tube formation<sup>100</sup>.

Atherosclerosis is a chronic circulatory disease that is characterized by the build-up of fatty or high-cholesterol plaques on the inner surface of large- to medium-sized blood vessels. The pathogenesis of atherosclerosis is not fully understood, but recent studies have indicated that altered H<sub>2</sub>S metabolism is involved in both the initiation and progression of this vascular disorder. Atherosclerosis in apolipoprotein E (APOE)-knockout mice is accompanied by decreased H<sub>2</sub>S levels in the blood, and treatment of these mice with NaHS was shown to attenuate the thickening and stiffening of arterial vessels<sup>101</sup>. Mani *et al.*<sup>102</sup> showed that CSE-knockout mice that were fed an atherogenic paigen-type diet for 12 weeks developed early fatty-streak lesions in the aortic root, increased oxidative stress and expression of adhesion molecules, and enhanced aortic intimal proliferation. By contrast, wide-type mice fed the same atherogenic diet, or CSE-knockout mice fed a normal diet, did not develop any atherosclerotic damage. The anti-atherosclerotic effects of H<sub>2</sub>S are manifested through: the inhibition of neointimal hyperplasia and smooth muscle proliferation; a decrease in levels of oxidized LDLs, vascular calcification and vascular inflammation; and a suppression of the adhesion of monocytes to endothelial cells<sup>102,103</sup>.

An enhanced understanding of the anti-atherosclerotic role of H<sub>2</sub>S has helped advance H<sub>2</sub>S-based therapies targeting atherosclerosis. In APOE-knockout mice, treatment with NaHS (56 μmol per kg per day, i.p. administration) or GYY4137 (133 μmol per kg per day, i.p.

**Two-kidney-one-clip model**  
A model of hypertension induced by chronically constricting one renal artery while the other renal artery remains fully perfused.

administration) reduced the atherosclerotic plaque load and partially restored acetylcholine-induced endothelium-dependent relaxation of the aorta<sup>101,103</sup>. H<sub>2</sub>S donors also suppressed the expression of intercellular adhesion molecule 1 (ICAM1), tumour necrosis factor (TNF) and interleukin-6 (IL-6) in the aorta; the expression of CX3C-chemokine receptor 1 (CX3CR1) and CX3C-chemokine ligand 1 (CX3CL1) in macrophages and lesion plaques; and the generation of superoxides in the aorta of these animals<sup>101,103,104</sup>. Moreover, in these mice, early treatment with NaHS at a dose of 1 mg per kg per day (i.p. administration) generated better therapeutic benefit against atherosclerotic damage than did NaHS after atherosclerosis had fully developed<sup>104</sup>.

**Lipid metabolism disorders and liver diseases.** The liver has essential roles in lipid metabolism, and hepatic production of H<sub>2</sub>S plays a key part in managing lipid metabolism. Indeed, genetic deficiencies in either CBS or CSE result in hyperhomocysteinaemia. CBS-knockout mice that are fed normal chow exhibit abnormal lipid metabolism, with increased serum and hepatic levels of triglycerides and non-essential fatty acids, as well as spontaneous hepatic fibrosis and steatosis<sup>105,106</sup>. Nevertheless, liver morphology and function seem to be normal in chow-fed CSE-knockout mice<sup>107</sup>. The impact of CSE deficiency on lipid metabolism becomes detectable only after these mice are fed a high-fat atherogenic diet: with such an atherogenic feeding regime, they exhibit increased plasma levels of total and LDL cholesterol, decreased high-density lipoprotein (HDL) cholesterol and early development of atherosclerosis<sup>102</sup>. Strikingly, in humans, plasma H<sub>2</sub>S levels are positively correlated with HDL cholesterol, and negatively correlated with the ratio of LDL to HDL cholesterol<sup>108</sup>.

Downregulation of CSE expression and decreased endogenous H<sub>2</sub>S levels in the liver are common consequences observed in bile duct-ligated rats with cirrhosis and associated portal hypertension<sup>109</sup> or in rats with carbon tetrachloride-induced liver cirrhosis<sup>110</sup>. Several studies have shown the beneficial effects of H<sub>2</sub>S supplementation therapy in these models of liver diseases<sup>109–111</sup>. However, there are circumstances of elevated H<sub>2</sub>S production in which treatment with H<sub>2</sub>S donors can be detrimental. For example, when mice with septic shock were treated with NaHS at a dose of 14 μmol per kg (i.p. administration) this increased liver damage<sup>112</sup>, whereas pharmacological inhibition of CSE with DL-propargylglycine (50 mg per kg, i.p. administration) protected these animals from liver damage. In rat endotoxaemia, portal infusion of sodium sulfide (Na<sub>2</sub>S) through a splenic cannula at a rate of 2 μmol per kg per minute for 10 minutes caused hepatic vasoconstriction and increased portal pressure *in vivo*<sup>113</sup>. Conversely, treatment of the rats with DL-propargylglycine (50 mg per kg, i.p. administration) significantly attenuated the vasoconstrictive effect of endothelin 1 in endotoxin-treated animals. The proposed underlying mechanism for the detrimental effects of H<sub>2</sub>S in these situations is that the perturbed hepatic sinusoidal perfusion during sepsis is further decreased by H<sub>2</sub>S supplementation, thus leading to exacerbated tissue hypoxia<sup>113</sup>.

**Diabetes.** Diabetes mellitus is caused by decreased bioavailability of insulin from the pancreas and/or diminished insulin sensitivity of the peripheral tissues. Altered metabolism of H<sub>2</sub>S in the pancreas and in peripheral tissues is involved in both the pathogenesis of diabetes and its complications (FIG. 2). Overexpression of CSE and the consequential overproduction of H<sub>2</sub>S in pancreatic β-cells, as detected in genetic diabetic rat models (Zucker diabetic rats), constitute pathogenic factors for diabetes<sup>114</sup>. Loss of functional β-cell mass is directly responsible for the pathogenesis of type 1 diabetes and progression of type 2 diabetes<sup>115</sup>. Although a β-cell-killing effect of H<sub>2</sub>S has not been directly demonstrated *in vivo*, cultured insulin-secreting INS-1E cells undergo increased apoptosis in response to H<sub>2</sub>S — a finding that is certainly indicative of the potential impact of H<sub>2</sub>S on β-cell mass<sup>116</sup>.

Also relevant to pancreatic insulin release is the H<sub>2</sub>S-induced stimulation of K<sub>ATP</sub> channels in β-cells, and their subsequent membrane hyperpolarization<sup>55,114</sup>. In addition, H<sub>2</sub>S has been shown to inhibit L-type VDCCs in mouse pancreatic β-cells<sup>44</sup>. H<sub>2</sub>S-induced membrane hyperpolarization and inhibition of VDCCs synergistically decrease calcium entry and insulin release from β-cells<sup>44</sup>. Following the consideration of the negative effects of H<sub>2</sub>S on pancreatic insulin production and insulin release, a causative role of pancreatic H<sub>2</sub>S in diabetes was proposed in 2004 (REFS 114,117). Zucker diabetic fatty rats have a type 2 diabetic phenotype. Pancreatic β-cell expression of the gene encoding CSE and β-cell production of H<sub>2</sub>S were both found to be significantly higher in Zucker diabetic fatty rats than in non-diabetic Zucker lean or non-diabetic Zucker fatty rats<sup>114,117</sup>. Patients with type 1 or type 2 diabetes (but without nephropathy) had significantly enhanced activities of CSE and CBS compared with healthy controls<sup>118,119</sup>. Further study of Zucker diabetic fatty rats has shown that inhibition of CSE activity significantly decreased the production of H<sub>2</sub>S, increased plasma insulin levels, and lowered hyperglycaemia<sup>114</sup>. Diabetes induced by streptozotocin was much slower to develop in CSE-knockout mice than in wild-type mice<sup>120</sup>. Moreover, streptozotocin induced a higher amount of pancreatic H<sub>2</sub>S production and killed more β-cells in wild-type mice than in CSE-knockout mice<sup>120</sup>. Therefore, at least some of the diabetes-inducing effects of streptozotocin are mediated by CSE and/or H<sub>2</sub>S, and an increased level of pancreatic H<sub>2</sub>S is a causative factor for diabetes development.

What happens in the pancreas in terms of the metabolism and functions of H<sub>2</sub>S is quite different to what happens in other parts of the body. Once diabetes is established, various diabetic complications can develop, including cardiomyopathy, nephropathy and vascular disorders associated with endothelial dysfunction. These complications are closely related to systemic H<sub>2</sub>S deficiency, as hyperglycaemic cells oxidize and consume more H<sub>2</sub>S (REFS 121,122). Overexpression of CSE or treatment with H<sub>2</sub>S prevented dysfunction of cultured microvascular endothelial cells that was induced by high levels of glucose; improved hyperglycaemia-impaired endothelium-dependent aortic vascular relaxations *in vitro* and *ex vivo*<sup>123</sup>; and accelerated wound healing by restoring the functions of endothelial progenitor


#### Hyperhomocysteinaemia

A condition characterized by abnormally high levels of homocysteine in the blood. The major causes of this condition are deficiencies of vitamins B6, B9 and B12, and mutations in the gene encoding the enzyme 5-methyltetrahydrofolate.

#### Streptozotocin

A chemical commonly used to induce diabetes in laboratory animals, as it is toxic to the insulin-producing β-cells in the pancreas.





**Figure 2 | The pathogenic roles of H<sub>2</sub>S at different stages of diabetes development.** Elevated endogenous hydrogen sulfide (H<sub>2</sub>S) levels in pancreatic β-cells and hepatocytes have crucial roles in the onset of diabetes. At late stages of the disease, endogenous H<sub>2</sub>S levels are lower in the affected organs and tissues, such as in vascular endothelial cells or cardiomyocytes, contributing to the development of diabetic complications in these organs. Correspondingly, H<sub>2</sub>S-based therapy for diabetes should be staged in two phases. At the onset phase of diabetes (part **a**), selective inhibition of the endogenous production of H<sub>2</sub>S in pancreatic β-cells and the liver would both increase insulin availability and decrease glucose production. By contrast, at later stages (part **b**), selective delivery of H<sub>2</sub>S donors to the peripheral organs would be beneficial for preventing and treating diabetic complications.

cells and the activation of angiotensin 1 signalling<sup>124</sup>. Notably, in rats with streptozotocin-induced diabetes, NaHS treatment at 100 μmol per kg per day (i.p. administration) also improved cardiac function and reversed the diabetes-related cardiac morphological changes by protecting cardiomyocytes against oxidative damage and preserving mitochondrial functions<sup>125</sup>.

**Neurodegenerative diseases.** Brain levels of H<sub>2</sub>S in individuals with Alzheimer disease are lower than in age-matched healthy people, although the expression levels of CBS between these groups are not different<sup>126</sup>. As Alzheimer disease is associated with reduced production of H<sub>2</sub>S, there may be an associated decrease in neuronal cytoprotection, such that the deleterious effects of damage and neuroinflammation induced by amyloid-β and oxidative stress are increased<sup>127–129</sup>. Whether the low levels of H<sub>2</sub>S in the brain observed in Alzheimer disease are a cause or a consequence of the disorder is not clear. In a rat model of ischaemic vascular dementia, plasma H<sub>2</sub>S levels were lower and inversely correlated with the decrease in the number of viable neurons in the hippocampus. Intraperitoneal injection with NaHS (14 μmol per kg) markedly protected against neuronal injury and improved the performance of learning and memory, tested by the Morris water maze, in these animals<sup>130</sup>.

Parkinson disease is another neurodegenerative disease in which the metabolism of H<sub>2</sub>S may be involved. In a mouse model of Parkinson disease, H<sub>2</sub>S levels in the substantia nigra and striatum were significantly lower than in control mice<sup>131</sup>. H<sub>2</sub>S that was given via injection<sup>131</sup> or inhalation<sup>132</sup> impeded or prevented Parkinson-disease-like abnormalities, including movement dysfunction and microglial activation.

Unexpectedly — given the dominant expression of CBS in the brain — a recent study revealed the importance of CSE for the manifestation of Huntington disease

(HD), an autosomal-dominant disease associated with a mutation in the gene encoding huntingtin<sup>21</sup>. In this study, CSE deficiency was found in brain tissues (the striatum and cerebral cortex) but not in the cerebellum of patients with HD, keeping in line with the relative susceptibility of these brain regions to HD damage. Furthermore, in murine models of HD (Q175 mice and R6/2 HD mice), CSE expression was downregulated in the striatum, cortex, hippocampus, hypothalamus and brainstem, but not in the cerebellum. Interestingly, CSE-knockout mice display impaired rotarod performance and an abnormal hindlimb clasp and clenching phenotype that is reminiscent of murine models of HD. These HD-related phenotypic changes were reversed by exogenously supplied cysteine<sup>21</sup>.

In traumatic spinal cord injury, neuronal damage is initially caused by the trauma itself, but considerable additional damage is caused by the ensuing inflammatory reaction. In a mouse model of spinal cord injury, Campolo *et al.*<sup>133</sup> demonstrated the potential of using H<sub>2</sub>S to decrease the inflammatory component of the injury, and to accelerate the recovery of lost motor function. Post-trauma treatment with a nonsteroidal anti-inflammatory drug (NSAID), naproxen, enhanced recovery of lost motor function in the mice, and decreased several indices of spinal cord inflammation. However, in mice that were treated with an H<sub>2</sub>S-releasing derivative of naproxen (ATB-346), there was a marked acceleration in the recovery of lost motor function and further enhancement of anti-inflammatory effects.

**Gastrointestinal disorders.** H<sub>2</sub>S, including that produced by enteric bacteria (BOX 2), has been implicated as a mediator of several physiological functions in the digestive tract. There is emerging evidence of the utility of H<sub>2</sub>S donors in treating several gastrointestinal disorders, particularly those associated with inflammation (FIG. 3).

For example, abdominal pain is a common but poorly treated condition, and chronic abdominal pain is often described as irritable bowel syndrome.

The role of H<sub>2</sub>S in modulating visceral pain is controversial: conflicting data suggest that it is both pro- and anti-nociceptive<sup>39,91,134–137</sup>. However, these differences may be related to the models used and the types and doses of H<sub>2</sub>S donors that were used<sup>91</sup>. Several studies have suggested potent anti-nociceptive effects of H<sub>2</sub>S donors in rodent models of visceral pain<sup>39,91,134,136</sup>. For example, colonic distention-induced pain in rats was substantially attenuated by several H<sub>2</sub>S donors, the actions of which were mediated, at least in part, through the activation of K<sub>ATP</sub> channels<sup>39</sup>. Similarly, gastric distention-induced pain in rats was markedly reduced by H<sub>2</sub>S donors and exacerbated by an inhibitor of CSE activity<sup>91</sup>. An H<sub>2</sub>S-releasing salt of trimebutine (an opioid anti-spasmodic drug) was shown to be safe and well tolerated in a Phase I clinical trial (ClinicalTrials.gov identifier: NCT01738425)<sup>138</sup>, and is now being tested as an abdominal analgesic in Phase II clinical trials (ClinicalTrials.gov identifiers: NCT01926444 and NCT02276768).

Acute damage to the lining of the stomach can be induced by certain drugs (such as NSAIDs), stress and gastric ischaemia–reperfusion. H<sub>2</sub>S is an important

mediator of gastric mucosal defence; that is, the ability of the gastric mucosa to resist injury induced by endogenous and exogenous substances<sup>139,140</sup>. Pharmacological inhibition of H<sub>2</sub>S synthesis increases the susceptibility of the stomach to injury, whereas H<sub>2</sub>S donors (such as NaHS or diallyl disulfide) can protect the stomach from damage<sup>139–141</sup>. The underlying mechanism of the cytoprotective action of H<sub>2</sub>S probably involves its ability to inhibit leukocyte adherence to the vascular endothelium<sup>142</sup> — a key event in the pathogenesis of NSAID-induced gastric mucosal damage<sup>143</sup>. H<sub>2</sub>S can also trigger gastric and duodenal secretion of bicarbonate, which neutralizes excess mucosa-damaging acid<sup>144,145</sup>. Moreover, H<sub>2</sub>S increases gastric mucosal blood flow, enhancing mucosal resistance to injury<sup>139</sup>. H<sub>2</sub>S-releasing derivatives of NSAIDs have been shown to produce markedly less gastrointestinal damage than their corresponding parent NSAIDs<sup>146–151</sup>. True gastric ulcers, which penetrate into the submucosal layer of the stomach wall, take many days or weeks to heal, and clinically the healing of such ulcers can be accelerated to some extent by drugs that suppress gastric acid secretion. This healing is partially dependent upon H<sub>2</sub>S, the synthesis of which is increased at the margins of the ulcer, where there is increased expression of CSE and CBS<sup>152</sup>. Oral administration of L-cysteine or H<sub>2</sub>S donors (in this case, Lawesson's reagent or 4-hydroxythiobenzamide) to rats with gastric ulcers resulted in a significant acceleration of ulcer healing<sup>152</sup>. Whereas NSAIDs are known to retard the healing of gastric ulcers in humans and animals, H<sub>2</sub>S-releasing NSAIDs have been shown to accelerate ulcer healing in mice<sup>148</sup>. Treatment with the H<sub>2</sub>S donor NaHS has also been shown to significantly reduce the severity of reflux oesophagitis in rats, and inhibition of CSE in these animals led to the exacerbation of tissue injury<sup>153</sup>.

NSAIDs also induce notable ulceration and bleeding in the small intestine, and there are no preventive or curative treatments available that have been proven to be effective for this potentially lethal condition<sup>149,154</sup>. Treatment with the H<sub>2</sub>S donor diallyl disulfide can substantially reduce NSAID-induced enteropathy in rats<sup>155</sup>, and H<sub>2</sub>S-releasing NSAIDs induce negligible damage to the small intestine — even when such NSAIDs are co-administered with drugs such as aspirin and proton-pump inhibitors, which can markedly exacerbate NSAID-induced intestinal damage and bleeding<sup>149</sup>.


H<sub>2</sub>S appears to have a particularly important role as an anti-inflammatory, pro-healing molecule in the colon. In experimental colitis in rats, the local synthesis of H<sub>2</sub>S is dramatically upregulated<sup>18</sup> at the sites of ulceration<sup>156</sup>. In this model, H<sub>2</sub>S promotes the resolution of colonic inflammation and the healing of ulcers<sup>18,156</sup>. Inhibition of H<sub>2</sub>S synthesis in healthy rats led to gastrointestinal mucosal inflammation, reduced expression of cyclooxygenase 2 and reduced synthesis of prostaglandin in the mucosa<sup>18,91</sup>. Administration of the H<sub>2</sub>S donors Lawesson's reagent, NaHS or diallyl trisulfide to rats or mice with colitis resulted in faster resolution of inflammation and colonic tissue injury healing, as well as a downregulation of pro-inflammatory cytokine and chemokine expression relative to control animals<sup>18,157</sup>.

#### Box 2 | H<sub>2</sub>S and bacterial–epithelial signalling

The greatest source of hydrogen sulfide (H<sub>2</sub>S) synthesis 'within' the human body may actually be an external source: the microbiota. In addition to contributing to the pool of H<sub>2</sub>S, polysulfides and bound sulfane–sulfur<sup>182,183</sup>, bacteria-derived H<sub>2</sub>S has the capacity to influence many physiological and pathophysiological processes, particularly in the gastrointestinal tract. Bacteria-derived H<sub>2</sub>S may contribute to several aspects of mucosal defence and repair, and certainly to the bioenergetics of gastrointestinal epithelial cells<sup>184</sup>. Conversely, H<sub>2</sub>S donors appear to be able to influence the microbiota<sup>155,185</sup> — an effect that might be exploited in drug design to promote health.

Sulfate-reducing bacteria (SRBs) that produce H<sub>2</sub>S reside in the gastrointestinal tract, where there are also sulfate-consuming bacteria. In a study of healthy individuals in the United States, approximately 50% of those studied had their gut colonized by SRBs, with *Desulfovibrio piger* — a member of the class of δ-Proteobacteria — being the primary H<sub>2</sub>S producer<sup>186</sup>. Bacteria can also make polysulfides<sup>187</sup>. Just as it is now clear that circulating levels of H<sub>2</sub>S in mammals were markedly over-estimated in the past<sup>188</sup>, the concentrations of H<sub>2</sub>S produced in the lumen of the gut were grossly overestimated for decades, contributing to the notion that H<sub>2</sub>S was a primary driver of colonic inflammation and cancer<sup>189–191</sup>. At present, the balance of evidence suggests that H<sub>2</sub>S is an important metabolic fuel for the epithelial cells that line the gastrointestinal tract and that seem to be particularly well adapted to this purpose, perhaps because of the hypoxic environment in which they reside<sup>86,184</sup>. The epithelium can therefore function not only as a physical barrier against potentially harmful agents that might pass from the lumen of the gut into the body, but also as a metabolic barrier, oxidizing bacteria-derived H<sub>2</sub>S and, in doing so, generating ATP<sup>151</sup>. Bacterial H<sub>2</sub>S can also stimulate the proliferation of gastrointestinal epithelial cells, and may contribute to the repair of any damage to the epithelial layer<sup>192</sup>.

Conversely, the microbiota can be the target of actions of H<sub>2</sub>S. Studies in rodents have demonstrated that intestinal microbiota in the colon form linear biofilms that appear to promote harmonious coexistence of the bacteria with the gastrointestinal mucosa<sup>185</sup>. When the mucosa is inflamed, the production of mucus is decreased and microbiota biofilms become fragmented. Delivery of H<sub>2</sub>S into the colon promoted the resolution of inflammation, increased production of mucus, and restored normal biofilm structure, and this biofilm restoration was accompanied by reduced growth of planktonic bacteria<sup>185</sup>. In another study, administration of an H<sub>2</sub>S donor to rats was shown to cause profound shifts in the microbiota, correcting the detrimental dysbiosis that had been triggered by the chronic administration of a nonsteroidal anti-inflammatory drug<sup>155</sup>.



**Figure 3 | Anti-inflammatory and cytoprotective targets of H<sub>2</sub>S.** Hydrogen sulfide (H<sub>2</sub>S) is thought to act through several pathways, some of which are illustrated above, to reduce inflammation and protect tissues from injury (such as ulceration in the gastrointestinal tract). H<sub>2</sub>S can suppress leukocyte adherence to the vascular endothelium, leukocyte extravasation and consequent formation of oedema. It can substitute for oxygen in driving mitochondrial respiration, thereby attenuating oxidative-stress-related tissue injury. The ability of H<sub>2</sub>S to inhibit the activity of phosphodiesterases (PDEs) can contribute to its ability to relax vascular smooth muscle, resulting in enhanced blood flow. Resolution of inflammation can be enhanced by H<sub>2</sub>S through actions such as the promotion of neutrophil apoptosis, and driving macrophage differentiation towards the M2 (anti-inflammatory) phenotype. H<sub>2</sub>S can modulate the activity of a number of transcription factors: it inhibits nuclear factor-κB (NF-κB), leading to a reduced production of pro-inflammatory cytokines, and sulfhydrates Kelch-like ECH-associated protein 1 (KEAP1), which then releases active nuclear factor erythroid 2-related factor 2 (NRF2), resulting in increased expression of antioxidant-response elements (AREs). Increased production of H<sub>2</sub>S occurs around sites of damage, such as around ulcers in the gastrointestinal tract, and can accelerate the healing of such damage via the stimulation of angiogenesis. Anti-nociceptive effects of H<sub>2</sub>S have also been demonstrated. Adapted from REF. 193, American Physiological Society.

Impaired colonic H<sub>2</sub>S synthesis, as observed in rats with hyperhomocysteinaemia, was associated with marked exacerbation of colitis, which could be reversed by administration of the H<sub>2</sub>S donor diallyl disulfide<sup>158</sup>. IL-10-deficient mice, which spontaneously develop colitis, exhibited a similar defect in colonic H<sub>2</sub>S production that could be reversed by administration of IL-10 (REF. 158). Thus, there is a substantial body of evidence suggesting that the anti-inflammatory or pro-resolution effects of H<sub>2</sub>S are mediated to a large extent via downregulation of the expression of a range of pro-inflammatory cytokines (for example, IL-1β, TNF, interferon-γ (IFNγ), IL-12 and IL-23), although the expression of IL-10 is either spared or increased<sup>147,157,158</sup>.

As discussed further below, several studies have demonstrated notable chemopreventive effects of H<sub>2</sub>S-releasing drugs in animal models of colon cancer.

Conversely, an upregulation of the expression of CBS, and the accompanying increase in H<sub>2</sub>S production, have been suggested to play a key part in colonic tumour growth, in part by driving angiogenesis<sup>26</sup>.

**Human genetic diseases linked to H<sub>2</sub>S-generating enzymes.** Mutations in the human CSE gene can cause hereditary cystathioninuria and hypercystathioninaemia<sup>159,160</sup>. Similarly, inborn errors in the CBS gene are associated with the human hereditary diseases hyperhomocysteinaemia and homocystinuria<sup>161</sup>. As well as causing higher levels of cystathionine or homocysteine in the blood and urine, these diseases are associated with systemic inflammation, cardiovascular complications and damage to other organs. Conversely, overexpression of the CBS gene is a major cause of human Down syndrome, which is characterized by low levels of homocysteine in

the blood<sup>162</sup>. In addition, intronic polymorphisms and nonsense mutations in *MST* have been suggested to be responsible for a rare inheritable disorder known as mercaptolactate-cysteine disulfiduria<sup>163</sup>.

### H<sub>2</sub>S-based therapeutics

An appreciation of the physiological and pathological importance of H<sub>2</sub>S has been followed very quickly by attempts to develop novel therapeutics that aimed to deliver H<sub>2</sub>S, or to suppress its endogenous production (TABLE 1). Furthermore, the impetus for the founding of Ikaria Therapeutics was the finding that H<sub>2</sub>S given via inhalation could induce a state of 'suspended animation' in mice<sup>164</sup> by markedly reducing the metabolic rate. This company attempted to develop Na<sub>2</sub>S for critical-care applications, such as for the reduction of myocardial injury following infarction<sup>165</sup>. However, in 2011, two clinical trials (ClinicalTrials.gov identifiers: NCT01007461 and NCT00858936) were halted, and Ikaria Therapeutics does not appear to be pursuing H<sub>2</sub>S-based therapeutics at present.

Over the past decade, several other companies that focus on exploiting the potent anti-inflammatory and cytoprotective actions of H<sub>2</sub>S have been founded (TABLE 1). Antibe Therapeutics, CTG Pharma and Sulphydris have all developed H<sub>2</sub>S-releasing derivatives of a number of drugs, with a major focus on NSAIDs<sup>148–150,157</sup>. The main targets for these drugs are pain and inflammation, with the primary benefit of H<sub>2</sub>S release being the reduction in the gastrointestinal ulceration that is normally caused by NSAIDs. (However, CTG Pharma and Sulphydris no longer appear to be active.)

The lead drug of Antibe Therapeutics (ATB-346; a naproxen derivative; TABLE 1) is being developed for the treatment of osteoarthritis, and has completed Phase I clinical trials in healthy volunteers (see the [Antibe Therapeutics press release](#) for further information). In animal studies of disorders such as adjuvant-induced arthritis, the drug produced anti-inflammatory effects that were comparable to those achieved with equimolar doses of the parent drug<sup>148,149</sup>. However, unlike the parent drug, ATB-346 produced negligible damage in the gastrointestinal tract, even at very high doses and in animals with impaired mucosal defence<sup>148,149,166</sup>. Naproxen was selected as the base NSAID, because it is the only member of the NSAID class that does not significantly increase the risk of serious cardiovascular events such as myocardial infarction and stroke<sup>167</sup>. In a Phase I clinical trial, ATB-346 administration to healthy subjects in doses escalating from 25 mg to 2,000 mg did not produce any notable adverse events, or any irregular cardiovascular, renal, haematological or hepatic effects. Antibe Therapeutics has additional drugs in preclinical development for treating acute pain (such as that associated with gout or sports injuries) and for veterinary pain and inflammation, as well as a novel anti-thrombotic drug that exhibits greatly increased gastrointestinal safety (TABLE 1).

H<sub>2</sub>S-releasing NSAID derivatives are also the principal focus of drug development efforts by a group at the City University of New York, USA. However, the main therapeutic application for these drugs, which have an







NSAID linked to both a NO-releasing moiety and an H<sub>2</sub>S-releasing moiety, is the treatment and chemoprevention of cancer. As well as being effective in *in vitro* and animal models of various cancers, these compounds exhibit significantly reduced adverse gastrointestinal effects<sup>168,169</sup>. The lead drug of this group is NBS-1120 (TABLE 1).

Gicare Pharma is attempting to exploit the reported ability of H<sub>2</sub>S to reduce visceral pain<sup>39,134,136</sup>. Its lead drug, GIC-1001, is a salt — the counter-ions being thiobenzamide and trimebutine. Trimebutine is an opioid anti-spasmodic that has been used to treat a range of gastrointestinal conditions, including irritable bowel syndrome, for over 40 years. Shown to be safe in a Phase I clinical trial (ClinicalTrials.gov identifier: NCT01738425), this drug is now in Phase II clinical trials as a pre-colonoscopy analgesic (ClinicalTrials.gov identifier: NCT01926444 and NCT02276768). The rationale for this is that sedation during endoscopy is a routine practice, but can also be expensive and inconvenient. The use of GIC-1001 as pre-colonoscopy analgesic is proposed to reduce or even remove the need for sedation, possibly allowing the patient to leave hospital sooner, and translating to considerable savings for both the patient and the health-care provider. Trimebutine has been used as a treatment for irritable bowel syndrome<sup>170</sup>, raising the possibility that the use of GIC-1001 may be extended to that indication in the future.

Several H<sub>2</sub>S-based therapeutics target disorders that are characterized by oxidative stress and associated tissue injury. For example, largely on the basis of research by Elrod and colleagues<sup>171</sup>, SulfaGENIX (in New Orleans, Louisiana, USA) is developing zerovalent sulfur (SG-1002) as a medicinal food, with the initial aim of targeting heart failure. Preclinical studies in relevant animal models of heart failure have confirmed that SG-1002 is effective in decreasing infarct size, improving cardiac function, increasing angiogenesis, decreasing inflammation and downregulating oxidative stress after infarction. A Phase I trial of SG-1002 (ClinicalTrials.gov identifier: NCT02278276) evaluated doses of 200 mg, 400 mg and 800 mg per day in healthy volunteers and reported dose-dependent increases in plasma H<sub>2</sub>S levels, and only minor adverse effects. A second study has been designed (ClinicalTrials.gov identifier: NCT01989208) to evaluate the ability of SG-1002 to elevate plasma H<sub>2</sub>S levels (in effect, reversing the defects in circulating H<sub>2</sub>S) and to reduce markers of oxidative stress and heart failure.

Reducing oxidative stress is also the foundation of a series of novel compounds developed by Wood, Whiteman and colleagues at the University of Exeter, UK. Their compounds comprise an H<sub>2</sub>S-releasing group linked to a mitochondrion-targeting group. Mitochondria have a critical role in determining whether a cell survives or dies<sup>81</sup> and, as discussed, H<sub>2</sub>S can confer benefits to mitochondria by acting as an electron donor and downregulating the antioxidant-response pathway. The University of Exeter has patented (WO2013045951 A1) such H<sub>2</sub>S-releasing compounds for the treatment of humans, animals or plants, and the authors propose that the compounds would be useful for the treatment of disorders such as hypertension and haemorrhagic shock,

Table 1 | H<sub>2</sub>S-based therapeutics in development

Institution (location)	Structure	Clinical indications	Lead drug	Comment	Stage of development
Antibe Therapeutics (Toronto, Ontario, Canada)	 <p style="text-align: center;"><b>ATB-346</b></p>	Osteoarthritis	ATB-346	Naproxen derivative	Phase I
		Acute pain	ATB-352	Ketoprofen derivative	Preclinical
		Veterinary (pain)	ATB-338	Diclofenac derivative	Preclinical
		Thrombosis	ATB-350	Aspirin derivative	Preclinical
City University of New York (New York, USA)		Cancer	NBS-1120	Aspirin derivative	Preclinical
Gicare Pharma (Montreal, Quebec, Canada)		Colonic pain	GIC-1001	Trimebutine salt; licensed from Antibe Therapeutics	Phase II for analgesia during colonoscopy*
National University of Singapore (Singapore)		Hypertension, inflammation, cancer	GYY4137	Slow-releasing H <sub>2</sub> S donor	Unknown
Sova Pharmaceuticals (La Jolla, California, USA)	No structure available	Pain, metabolic disorders	Unknown	Inhibitor of CSE activity	Unknown
SulfaGENIX (New Orleans, Louisiana, USA)		Oxidative stress	SG-1002	Polyvalent sulfur	Phase II for heart failure†
University of Exeter (Exeter, UK)		Inflammation, oxidative stress	AP39	Mitochondrion-targeted H <sub>2</sub> S release	Preclinical

CSE, cystathionine  $\gamma$ -lyase; H<sub>2</sub>S, hydrogen sulfide. \*ClinicalTrials.gov identifiers: NCT01926444 and NCT02276768. †ClinicalTrials.gov identifier: NCT01989208.

as well as conditions characterized by inflammation and oedema<sup>80</sup>. AP39 is the most advanced of these compounds (TABLE 1). It has been shown to elevate H<sub>2</sub>S levels within endothelial mitochondria, protect cells against oxidant-induced damage and prevent damage to mitochondrial DNA *in vitro*<sup>80</sup>.

Another university-based drug development programme with an H<sub>2</sub>S focus is that of Moore *et al.* at the National University of Singapore. This group developed

the H<sub>2</sub>S donor GYY4137, which is now widely used as a research tool to study the effects of H<sub>2</sub>S. Compared with conventional H<sub>2</sub>S donors, GYY4137 releases H<sub>2</sub>S more slowly. It is not clear whether this compound is in development or whether it is just a prototype for an H<sub>2</sub>S-based therapeutic. GYY4137 has been shown to exert anti-hypertensive actions in SHR<sup>172</sup>, and to reduce inflammation through its ability to reduce circulating levels of various pro-inflammatory cytokines and mediators<sup>173</sup>.

In this regard, GYY4137 has been shown to be an effective anti-inflammatory agent in a murine adjuvant-induced arthritis model<sup>174</sup>. The current status of the development of an H<sub>2</sub>S donor by this group is unclear, but a patent is held for the use of a slow-releasing H<sub>2</sub>S donor for the treatment of cancer (WO2014018569 A1).

Sova Pharmaceuticals is a company that was co-founded by Snyder, and is developing inhibitors of CSE for respiratory and metabolic disorders, as well as for diseases characterized by pain and inflammation, such as osteoarthritis and rheumatoid arthritis. The premise for this programme is that overproduction of H<sub>2</sub>S contributes to the pathogenesis of several diseases — in particular, neuropathic and neurodegenerative diseases — as well as to inflammation and inflammatory pain. The current status of drug development by Sova Pharmaceuticals is unclear; however, the company filed a patent for CSE inhibitors in July 2013.

There are also several therapeutics on the market that were not developed specifically as H<sub>2</sub>S-releasing drugs, but that could contribute to beneficial effects by releasing H<sub>2</sub>S. For example, anethole trithione (sold under a number of brand names, including Sialor (Pendopharm) and Sulfarlem (EurekaSante)) is a drug that has been used for decades for treating dry mouth. Anethole trithione can generate H<sub>2</sub>S, and is the same moiety that has been incorporated into H<sub>2</sub>S-releasing drugs (for example, NBS-1120 and AP39 in TABLE 1) for preventing cancers, reducing oxidative stress and attenuating inflammation. Whether or not H<sub>2</sub>S contributes to the desired clinical effects of anethole trithione is not clear. Like anethole trithione, oltipraz is a member of the dithiolethione class, and is used as a schistosomicide; however, it is not clear whether H<sub>2</sub>S release contributes to its mechanism of action.

Zofenopril (Menarini) is an inhibitor of angiotensin-converting enzyme (ACE), and Bucci *et al.*<sup>175</sup> demonstrated that a large component of the anti-hypertensive effects of this drug occur independently of ACE inhibition, and are instead attributable to the H<sub>2</sub>S released by this drug. *N*-acetylcysteine is a mucolytic drug used in the treatment of cystic and pulmonary fibrosis and also as an antidote for acetaminophen-induced liver damage. This drug can also generate H<sub>2</sub>S, and has been shown

to elicit marked anti-inflammatory effects in rodents<sup>142</sup>, although roles for H<sub>2</sub>S in mediating its above-mentioned clinical effects have not yet been established.

### Future directions

Given the ubiquitous nature of H<sub>2</sub>S, it is not surprising that it has important roles in a wide range of physiological and pathophysiological processes. The speed with which many H<sub>2</sub>S-based therapies have been developed is a reflection of the excitement that this unique mediator has ignited and of the promising data that have been generated in preclinical and early clinical testing. The novel therapeutics that have been developed thus far offer the promise of increased efficacy, reduced toxicity, or both, compared with existing therapies. They range from very simple (for instance, zerovalent sulfur) to quite sophisticated approaches (such as H<sub>2</sub>S release targeted to specific organelles).

In the near future, it is likely that organ-specific delivery of H<sub>2</sub>S will be achieved, and with that, the possibility of disease-specific H<sub>2</sub>S donors. It is also likely that the development of pH-, oxygen-, and free radical-sensitive donors will further facilitate the selective delivery of H<sub>2</sub>S. Agents that could selectively activate the different H<sub>2</sub>S-generating enzymes (namely, CSE, CBS and MST) are another intriguing possibility. Progress in the H<sub>2</sub>S field has so far been hampered by the lack of availability of selective inhibitors of the various enzymes that contribute to the synthesis of this gasotransmitter. With enzymes such as CSE being identified as potential therapeutic targets, there will be increased motivation to develop potent and highly selective inhibitors that will hopefully be of value in research as well as for diagnostic and therapeutic applications.

As drugs that release H<sub>2</sub>S or modulate its synthesis progress through the development path towards widespread clinical use, there will be a growing need to better understand the mechanisms of action of H<sub>2</sub>S, and to be able to accurately monitor levels of H<sub>2</sub>S *in vivo*. In addition to characterizing the effects of H<sub>2</sub>S in various tissues and organs, attention will need to be paid to the potential impact that modulation of H<sub>2</sub>S levels has on the microbiota (BOX 2), and in turn, the influence of any such changes on health and disease.

- Wang, R. Two's company, three's a crowd: can H<sub>2</sub>S be the third endogenous gaseous transmitter? *FASEB J.* **16**, 1792–1798 (2002). **This study conceptualizes gasotransmitters as a class of signalling molecules and proposes the importance of H<sub>2</sub>S in this context.**
- Kimura, H., Shibuya, N. & Kimura, Y. Hydrogen sulfide is a signaling molecule and a cytoprotectant. *Antioxid. Redox Signal.* **17**, 45–57 (2012).
- Olson, K. R., Donald, J. A., Dombkowski, R. A. & Perry, S. F. Evolutionary and comparative aspects of nitric oxide, carbon monoxide and hydrogen sulfide. *Respir. Physiol. Neurobiol.* **184**, 117–129 (2012).
- Yamanishi, M., Kabil, O., Sen, S. & Banerjee, R. Structural insights into pathogenic mutations in heme-dependent cystathionine-β-synthase. *J. Inorg. Biochem.* **100**, 1988–1995 (2006).
- Teng, H. *et al.* Oxygen-sensitive mitochondrial accumulation of cystathionine β synthase mediated by Lon protease. *Proc. Natl Acad. Sci. USA* **110**, 12679–12684 (2013).
- Wang, R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. *Physiol. Rev.* **92**, 791–896 (2012).
- Nagahara, N., Okazaki, T. & Nishino, T. Cytosolic mercaptopyruvate sulfurtransferase is evolutionarily related to mitochondrial rhodanese. Striking similarity in active site amino acid sequence and the increase in the mercaptopyruvate sulfurtransferase activity of rhodanese by site-directed mutagenesis. *J. Biol. Chem.* **270**, 16230–16235 (1995).
- Yang, G., Cao, K. & Wang, R. Cystathionine γ-lyase over-expression inhibits cell proliferation via a H<sub>2</sub>S-dependent modulation of ERK1/2 phosphorylation and p21 Cip/WAK1. *J. Biol. Chem.* **279**, 49199–49205 (2004).
- Callendo, G., Cirino, G., Santagada, V. & Wallace, J. L. Synthesis and biological effects of hydrogen sulfide (H<sub>2</sub>S): development of H<sub>2</sub>S-releasing drugs as pharmaceuticals. *J. Med. Chem.* **53**, 6275–6286 (2010).
- Levitt, M. D., Abdel-Rehim, M. S. & Furne, J. Free and acid-labile hydrogen sulfide concentrations in mouse tissues: anomalously high free hydrogen sulfide in aortic tissue. *Antioxid. Redox Signal.* **15**, 373–378 (2011).
- Insko, M. A., Deckwerth, T. L., Hill, P., Toombs, C. F. & Szabo, C. Detection of exhaled hydrogen sulphide gas in rats exposed to intravenous sodium sulphide. *Br. J. Pharmacol.* **157**, 944–951 (2009).
- Hosoki, R., Matsiki, N. & Kimura, H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. *Biochem. Biophys. Res. Commun.* **237**, 527–531 (1997). **This is an original description of the vasorelaxant effects of H<sub>2</sub>S.**
- Zhao, W., Zhang, J., Lu, Y. & Wang, R. The vasorelaxant effect of H<sub>2</sub>S as a novel endogenous gaseous K<sub>ATP</sub> channel opener. *EMBO J.* **20**, 6008–6016 (2001). **This study describes the first cloning of CSE in vascular tissues and the identification of K<sub>ATP</sub> channels as the molecular target of endogenous H<sub>2</sub>S for its vasorelaxant effects.**
- Yang, G. *et al.* Hydrogen sulfide protects against cellular senescence via S-sulphydration of Keap1 and activation of Nrf2. *Antioxid. Redox Signal.* **18**, 1906–1919 (2013).

15. Zhang, G., Wang, P., Yang, G., Cao, Q. & Wang, R. The inhibitory role of hydrogen sulfide in airway hyperresponsiveness and inflammation in a mouse model of asthma. *Am. J. Pathol.* **182**, 1188–1195 (2013).
16. Fiorucci, S., Distrutti, E., Cirino, G. & Wallace, J. L. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. *Gastroenterology* **131**, 259–271 (2006).
17. Schicho, R. *et al.* Hydrogen sulfide is a novel prosecretory neuromodulator in the guinea-pig and human colon. *Gastroenterology* **131**, 1542–1552 (2006).
18. Wallace, J. L., Vong, L., McKnight, W., Dickey, M. & Martin, G. R. Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. *Gastroenterology* **137**, 569–578 (2009).
19. Martin, G. R. *et al.* Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract. *Dig. Liver Dis.* **42**, 103–109 (2010).
20. Erickson, P. F., Maxwell, I. H., Su, L. J., Baumann, M. & Glode, L. M. Sequence of cDNA for rat cystathionine  $\gamma$ -lyase and comparison of deduced amino acid sequence with related *Escherichia coli* enzymes. *Biochem. J.* **269**, 335–340 (1990).
21. Paul, B. D. *et al.* Cystathionine  $\gamma$ -lyase deficiency mediates neurodegeneration in Huntington's disease. *Nature* **509**, 96–100 (2014).
22. Abe, K. & Kimura, H. The possible role of hydrogen sulfide as an endogenous neuromodulator. *J. Neurosci.* **16**, 1066–1071 (1996).
23. Robert, K. *et al.* Expression of the cystathionine  $\beta$  synthase (CBS) gene during mouse development and immunolocalization in adult brain. *J. Histochem. Cytochem.* **51**, 363–371 (2003).
24. Mani, S., Untereiner, A., Wu, L. & Wang, R. Hydrogen sulfide and the pathogenesis of atherosclerosis. *Antioxid. Redox Signal.* **20**, 805–817 (2014).
25. Chen, Y. & Wang, R. The message in the air: hydrogen sulfide metabolism in chronic respiratory diseases. *Resp. Physiol. Neurobiol.* **184**, 130–138 (2012).
26. Szabo, C. *et al.* Tumor-derived hydrogen sulfide, produced by cystathionine- $\beta$  synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. *Proc. Natl Acad. Sci. USA* **110**, 12474–12479 (2013).
27. Kondo, K. *et al.* H<sub>2</sub>S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. *Circulation* **127**, 1116–1127 (2013).
28. Fu, M., Zhang, W., Yang, G. & Wang, R. Is cystathionine  $\gamma$ -lyase protein expressed in the heart? *Biochem. Biophys. Res. Commun.* **428**, 469–474 (2012).
29. Nagahara, N., Ito, T., Kitamura, H. & Nishino, T. Tissue and subcellular distribution of mercaptopyruvate sulfurtransferase in the rat: confocal laser fluorescence and immunoelectron microscopic studies combined with biochemical analysis. *Histochem. Cell. Biol.* **110**, 243–250 (1998).
30. Shibuya, N. *et al.* 3-mercaptopyrivate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. *Antioxid. Redox Signal.* **11**, 703–714 (2009).
31. Shibuya, N., Mikami, Y., Kimura, Y., Nagahara, N. & Kimura, H. Vascular endothelium expresses 3-mercaptopyrivate sulfurtransferase and produces hydrogen sulfide. *J. Biochem.* **146**, 623–626 (2009).
32. Módos, K., Panopoulos, P., Coletta, C., Papapetropoulos, A. & Szabo, C. Hydrogen sulfide-mediated stimulation of mitochondrial electron transport involves inhibition of the mitochondrial phosphodiesterase 2A, elevation of cAMP and activation of protein kinase A. *Biochem. Pharmacol.* **86**, 1311–1309 (2013).
33. Fu, M. *et al.* Hydrogen sulfide (H<sub>2</sub>S) metabolism in mitochondria and its regulatory role in energy production. *Proc. Natl Acad. Sci. USA* **109**, 2943–2948 (2012).  
**This study shows that increases in intracellular calcium promote translocation of CSE to the mitochondrion, leading to increased mitochondrial H<sub>2</sub>S production and improved ATP production under hypoxic conditions.**
34. Tang, G., Wu, L., Liang, W. & Wang, R. Direct stimulation of K<sub>ATP</sub> channels by exogenous and endogenous hydrogen sulfide in vascular smooth muscle cells. *Mol. Pharmacol.* **68**, 1757–1764 (2005).
35. Yang, W., Yang, G., Xia, X., Wu, L. & Wang, R. Activation of K<sub>ATP</sub> channels by H<sub>2</sub>S in rat insulin-secreting cells and the underlying mechanisms. *J. Physiol.* **569**, 519–531 (2005).
36. Fitzgerald, R. *et al.* H<sub>2</sub>S relaxes isolated human airway smooth muscle cells via the sarcolemmal K<sub>ATP</sub> channel. *Biochem. Biophys. Res. Commun.* **446**, 393–398 (2014).
37. Dawe, G. S., Han, S. P., Bian, J. S. & Moore, P. K. Hydrogen sulphide in the hypothalamus causes an ATP-sensitive K<sup>+</sup> channel-dependent decrease in blood pressure in freely moving rats. *Neuroscience* **152**, 169–177 (2008).
38. Kimura, Y., Dargusch, R., Schubert, D. & Kimura, H. Hydrogen sulfide protects HT22 neuronal cells from oxidative stress. *Antioxid. Redox Signal.* **8**, 661–670 (2006).  
**This is a demonstration of the potent cytoprotective effects of H<sub>2</sub>S in the central nervous system.**
39. Distrutti, E. *et al.* Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating K<sub>ATP</sub> channels. *J. Pharm. Exp. Therap.* **316**, 325–335 (2006).
40. Medeiros, J. V. *et al.* Role of K<sub>ATP</sub> channels and TRPV1 receptors in hydrogen sulfide-enhanced gastric emptying of liquid in awake mice. *Eur. J. Pharmacol.* **693**, 57–63 (2012).
41. Jiang, B., Tang, G., Cao, K., Wu, L. & Wang, R. Molecular mechanism for H<sub>2</sub>S-induced activation of K<sub>ATP</sub> channels. *Antioxid. Redox Signal.* **12**, 1167–1178 (2010).
42. Gade, A. R., Kang, M. & Akbarali, H. I. Hydrogen sulfide as an allosteric modulator of ATP-sensitive potassium channels in colonic inflammation. *Mol. Pharmacol.* **83**, 294–306 (2013).
43. Mustafa, A. K. *et al.* H<sub>2</sub>S signals through protein S-sulfhydration. *Sci. Signal.* **2**, ra72 (2009).  
**This paper identifies the original discovery of the chemical interaction of H<sub>2</sub>S with proteins (that is, protein S-sulfhydration).**
44. Tang, G., Zhang, L., Yang, G., Wu, L. & Wang, R. Hydrogen sulfide-induced inhibition of L-type Ca<sup>2+</sup> channels and insulin secretion in mouse pancreatic  $\beta$  cells. *Diabetologia* **56**, 533–541 (2013).
45. Zhang, R. *et al.* Hydrogen sulfide inhibits L-type calcium currents depending upon the protein sulfhydryl state in rat cardiomyocytes. *PLoS ONE* **7**, e37073 (2012).
46. Elies, J. *et al.* Hydrogen sulfide inhibits Ca<sub>v</sub>3.2 T-type Ca<sup>2+</sup> channels. *FASEB J.* **28**, 5376–5387 (2014).
47. Avanzato, D. *et al.* Role of calcium channels in the protective effect of hydrogen sulfide in rat cardiomyoblasts. *Cell. Physiol. Biochem.* **33**, 1205–1214 (2014).
48. Sekiguchi, F. *et al.* Endogenous and exogenous hydrogen sulfide facilitates T-type calcium channel currents in Ca<sub>v</sub>3.2-expressing HEK293 cells. *Biochem. Biophys. Res. Commun.* **445**, 225–229 (2014).
49. Maeda, Y. *et al.* Hyperalgesia induced by spinal and peripheral hydrogen sulfide: evidence for involvement of Ca<sub>v</sub>3.2 T-type calcium channels. *Pain* **142**, 127–132 (2009).
50. Tang, G. *et al.* H<sub>2</sub>S is an endothelium-derived hyperpolarizing factor. *Antioxid. Redox Signal.* **19**, 1634–1646 (2013).  
**This study provides direct electrophysiological evidence for the role of H<sub>2</sub>S as an EDHF.**
51. Mustafa, A. K. *et al.* Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. *Circ. Res.* **109**, 1259–1268 (2011).  
**This study provides chemical and functional evidence for the role of H<sub>2</sub>S as an EDHF.**
52. Telezkin, V. *et al.* Hydrogen sulfide inhibits human BK<sub>Ca</sub> channels. *Adv. Exp. Med. Biol.* **648**, 65–72 (2009).
53. Li, Q. *et al.* A crucial role for hydrogen sulfide in oxygen sensing via modulating large conductance calcium-activated potassium channels. *Antioxid. Redox Signal.* **12**, 1179–1189 (2010).
54. Sitdikova, G. F., Weiger, T. M. & Hermann, A. Hydrogen sulfide increases Ca<sup>2+</sup>-activated K<sup>+</sup> (BK) channel activity of rat pituitary tumor cells. *Pflügers Arch.* **459**, 389–397 (2010).
55. Jackson-Weaver, O. *et al.* Hydrogen sulfide dilates rat mesenteric arteries by activating endothelial large-conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channels and smooth muscle Ca<sup>2+</sup> sparks. *Am. J. Physiol. Heart Circ. Physiol.* **304**, H1446–H1454 (2013).
56. Han, Y. F. *et al.* Evidence that endogenous hydrogen sulfide exerts an excitatory effect on gastric motility in mice. *Eur. J. Pharmacol.* **673**, 85–95 (2011).
57. Cheang, W. S. *et al.* 4-aminopyridine-sensitive K<sup>+</sup> channels contributes to NaHS-induced membrane hyperpolarization and relaxation in the rat coronary artery. *Vascul. Pharmacol.* **53**, 94–98 (2010).
58. Tang, G., Wu, L. & Wang, R. Interaction of hydrogen sulfide with ion channels. *Clin. Exp. Pharmacol. Physiol.* **37**, 753–763 (2010).
59. Bucci, M. *et al.* Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. *Arterioscler. Thromb. Vasc. Biol.* **30**, 1998–2004 (2010).  
**This paper reports the original discovery that H<sub>2</sub>S activates cGMP signalling via the inhibition of PDE, which contributes to the vasorelaxant and anti-inflammatory effects of H<sub>2</sub>S.**
60. Coletta, C. *et al.* Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. *Proc. Natl Acad. Sci. USA* **109**, 9161–9166 (2012).
61. Wang, R. Shared signaling pathways among gasotransmitters. *Proc. Natl Acad. Sci. USA* **109**, 8801–8802 (2012).
62. Lu, M. *et al.* Hydrogen sulfide inhibits plasma renin activity. *J. Am. Soc. Nephrol.* **21**, 993–1002 (2010).
63. Moccia, F. *et al.* Hydrogen sulfide regulates intracellular Ca<sup>2+</sup> concentration in endothelial cells from excised rat aorta. *Curr. Pharm. Biotechnol.* **12**, 1416–1426 (2011).
64. Bauer, C. C., Boyle, J. P., Porter, K. E. & Peers, C. Modulation of Ca<sup>2+</sup> signalling in human vascular endothelial cells by hydrogen sulfide. *Atherosclerosis* **209**, 374–380 (2010).
65. Liang, G. H., Xi, Q., Leffler, C. W. & Jaggar, J. H. Hydrogen sulfide activates Ca<sup>2+</sup> sparks to induce cerebral arteriole dilatation. *J. Physiol.* **590**, 2709–2720 (2012).
66. Altaany, Z., Ju, Y., Yang, G. & Wang, R. The coordination of S-sulfhydration, S-nitrosylation, and phosphorylation of endothelial nitric oxide synthase by hydrogen sulfide. *Sci. Signal.* **7**, ra87 (2014).
67. Zhang, D. *et al.* Detection of protein S-sulfhydration by a tag-switch technique. *Angew. Chem. Int. Ed. Engl.* **53**, 575–581 (2014).
68. Sen, N. *et al.* Hydrogen sulfide-linked sulfhydration of NF- $\kappa$ B mediates its antiapoptotic actions. *Mol. Cell* **45**, 13–24 (2012).
69. Kelleher, Z. T., Matsumoto, A., Stamler, J. S. & Marshall, H. E. NO<sub>2</sub> regulation of NF- $\kappa$ B by S-nitrosylation of p65. *J. Biol. Chem.* **282**, 30667–30672 (2007).
70. Beigi, F. *et al.* Dynamic denitrosylation via S-nitrosoglutathione reductase regulates cardiovascular function. *Proc. Natl Acad. Sci. USA* **109**, 4314–4319 (2012).
71. Wu, C. *et al.* Thioredoxin 1-mediated post-translational modifications: reduction, transnitrosylation, denitrosylation, and related proteomics methodologies. *Antioxid. Redox Signal.* **15**, 2565–2604 (2011).
72. Kabil, O. & Banerjee, R. Characterization of patient mutations in human persulfide dioxygenase (ETHE1) involved in H<sub>2</sub>S catabolism. *J. Biol. Chem.* **287**, 44561–44567 (2012).
73. Yan, S. K. *et al.* Effects of hydrogen sulfide on homocysteine-induced oxidative stress in vascular smooth muscle cells. *Biochem. Biophys. Res. Commun.* **351**, 485–491 (2006).
74. Chang, T., Untereiner, A., Liu, J. & Wu, L. Interaction of methylglyoxal and hydrogen sulfide in rat vascular smooth muscle cells. *Antioxid. Redox Signal.* **12**, 1093–1100 (2010).
75. Jeney, V. *et al.* Suppression of hemin-mediated oxidation of low-density lipoprotein and subsequent endothelial reactions by hydrogen sulfide (H<sub>2</sub>S). *Free Radic. Biol. Med.* **46**, 616–623 (2009).
76. Liu, Y. Y. & Bian, J. S. Hydrogen sulfide protects amyloid  $\beta$ -induced cell toxicity in microglia. *J. Alzheimers Dis.* **22**, 1189–1200 (2010).
77. Vacek, T. P., Gillespie, W., Tyagi, N., Vacek, J. C. & Tyagi, S. C. Hydrogen sulfide protects against vascular remodeling from endothelial damage. *Amino Acids* **39**, 1161–1169 (2010).
78. Xu, Z. S. *et al.* Hydrogen sulfide protects MC3T3 E1 osteoblastic cells against H<sub>2</sub>O<sub>2</sub>-induced oxidative damage-implications for the treatment of osteoporosis. *Free Radic. Biol. Med.* **50**, 314–323 (2011).
79. Módos, K., Asimakopoulou, A., Coletta, C., Papapetropoulos, A. & Szabo, C. Oxidative stress suppresses the cellular bioenergetic effect of the 3-mercaptopyrivate sulfurtransferase/hydrogen sulfide pathway. *Biochem. Biophys. Res. Commun.* **433**, 401–407 (2013).

80. Szczesny, B. *et al.* AP39, a novel mitochondria-targeted sulfide donor, stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells *in vitro*. *Nitr. Oxide* **41**, 120–130 (2014).
81. Trionnaire, S. *et al.* The synthesis and functional evaluation of a mitochondria-targeted hydrogen sulfide donor, [10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5-yl)phenoxy)decyl]triphenylphosphonium bromide (AP39). *Med. Chem. Commun.* **5**, 728–736 (2014).
82. Yang, G. *et al.* H<sub>2</sub>S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine  $\gamma$ -lyase. *Science* **322**, 587–590 (2008). **This study provides direct evidence for the physiological importance of endogenous H<sub>2</sub>S (mice deficient in CSE displayed significant elevations of blood pressure).**
83. Papapetropoulos, A. *et al.* Hydrogen sulfide is an endogenous stimulator of angiogenesis. *Proc. Natl Acad. Sci. USA* **106**, 21972–21977 (2009).
84. Madden, J. A., Ahlf, S. B., Dantuma, M. W., Olson, K. R. & Roerig, D. L. Precursors and inhibitors of hydrogen sulfide synthesis affect acute hypoxic pulmonary vasoconstriction in the intact lung. *J. Appl. Physiol.* **112**, 411–418 (2012).
85. Skovgaard, N. & Olson, K. R. Hydrogen sulfide mediates hypoxic vasoconstriction through a production of mitochondrial ROS in trout gills. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **303**, R487–R494 (2012).
86. Gubern, M. *et al.* Sulfide, the first inorganic substrate for human cells. *FASEB J.* **21**, 1699–1706 (2007). **This paper highlights the ability of cells to utilize H<sub>2</sub>S to drive mitochondrial production of ATP, which appears to be an important rescue mechanism during hypoxia or anoxia.**
87. M6dis, K., Coletta, C., Erd6lyi, K., Papapetropoulos, A. & Szabo, C. Intramitochondrial hydrogen sulfide production by 3-mercaptopyruvate sulfurtransferase maintains mitochondrial electron flow and supports cellular bioenergetics. *FASEB J.* **27**, 601–611 (2013).
88. Olson, K. R. Hydrogen sulfide as an oxygen sensor. *Clin. Chem. Lab. Med.* **51**, 623–632 (2013).
89. Chunyu, Z. *et al.* The regulatory effect of hydrogen sulfide on hypoxic pulmonary hypertension in rats. *Biochem. Biophys. Res. Commun.* **302**, 810–816 (2003).
90. Ariyaratnam, P., Loubani, M. & Morice, A. H. Hydrogen sulphide vasodilates human pulmonary arteries: a possible role in pulmonary hypertension? *Microvasc. Res.* **90**, 135–137 (2013).
91. Wallace, J. L. *et al.* Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. *Antioxid. Redox Signal.* **22**, 398–410 (2015).
92. Zhao, W. & Wang, R. H<sub>2</sub>S-induced vasorelaxation and underlying cellular and molecular mechanisms. *Am. J. Physiol. Heart Circ. Physiol.* **283**, H474–H480 (2002). **This paper reveals some of the mechanisms underlying H<sub>2</sub>S-induced vasodilation, including the contributions of Ca<sup>2+</sup> and the vascular endothelium.**
93. Zhao, W., Ndisang, J. F. & Wang, R. Modulation of endogenous production of H<sub>2</sub>S in rat tissues. *Can. J. Physiol. Pharmacol.* **81**, 848–853 (2003).
94. Du, J., Yan, H. & Tang, C. [Endogenous H<sub>2</sub>S is involved in the development of spontaneous hypertension]. *Beijing Da Xue Xue Bao* **35**, 102 (2003).
95. Ahmad, F. U. *et al.* Exogenous hydrogen sulfide attenuates oxidative stress in spontaneously hypertensive rats. *Int. J. Pharm. Sci. Res.* **4**, 2916–2926 (2013).
96. Yanfei, W., Lin, S., Junbao, D. & Chaoshu, T. Impact of L-arginine on hydrogen sulfide/cystathionine- $\gamma$ -lyase pathway in rats with high blood flow-induced pulmonary hypertension. *Biochem. Biophys. Res. Commun.* **345**, 851–857 (2006).
97. Wei, H. L., Zhang, C. Y., Jin, H. F., Tang, C. S. & Du, J. B. Hydrogen sulfide regulates lung tissue-oxidized glutathione and total antioxidant capacity in hypoxic pulmonary hypertensive rats. *Acta Pharmacol. Sin.* **29**, 670–679 (2008).
98. Wang, K. *et al.* Dysregulation of hydrogen sulfide producing enzyme cystathionine  $\gamma$ -lyase contributes to maternal hypertension and placental abnormalities in preeclampsia. *Circulation* **127**, 2514–2522 (2013).
99. Holwerda, K. M. *et al.* Hydrogen sulfide attenuates sFT1 induced hypertension and renal damage by upregulating vascular endothelial growth factor. *J. Am. Soc. Nephrol.* **25**, 717–725 (2014).
100. Altaany, Z. I., Yang, G. & Wang, R. Crosstalk between hydrogen sulfide and nitric oxide in endothelial cells. *J. Cell. Mol. Med.* **17**, 879–888 (2013).
101. Wang, Y. *et al.* Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. *Arterioscler. Thromb. Vasc. Biol.* **29**, 173–179 (2009).
102. Mani, S. *et al.* Decreased endogenous production of hydrogen sulfide accelerates atherosclerosis. *Circulation* **127**, 2523–2534 (2013).
103. Liu, Z. *et al.* The hydrogen sulfide donor, GYY4137, exhibits anti-atherosclerotic activity in high fat fed apolipoprotein E<sup>-/-</sup> mice. *Br. J. Pharmacol.* **169**, 1795–1809 (2013).
104. Zhang, H. *et al.* Hydrogen sulfide inhibits the development of atherosclerosis with suppressing CX3CR1 and CX3CL1 expression. *PLoS ONE* **7**, e41147 (2012).
105. Namekata, K. *et al.* Abnormal lipid metabolism in cystathionine  $\beta$ -synthase-deficient mice, an animal model for hyperhomocysteinemia. *J. Biol. Chem.* **279**, 52961–52969 (2004).
106. Robert, K. *et al.* Cystathionine  $\beta$  synthase deficiency promotes oxidative stress, fibrosis, and steatosis in mice liver. *Gastroenterology* **128**, 1405–1415 (2005).
107. Mani, S., Yang, G. & Wang, R. A critical life-supporting role for cystathionine  $\gamma$ -lyase in the absence of dietary cysteine supply. *Free Radic. Biol. Med.* **50**, 1280–1287 (2011).
108. Jain, S. K., Micinski, D., Lieblong, B. J. & Stapleton, T. Relationship between hydrogen sulfide levels and HDL-cholesterol, adiponectin, and potassium levels in the blood of healthy subjects. *Atherosclerosis* **225**, 242–245 (2012).
109. Fiorucci, S. *et al.* The third gas: H<sub>2</sub>S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. *Hepatology* **42**, 539–548 (2005).
110. Tan, G. *et al.* Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. *PLoS ONE* **6**, e25943 (2011).
111. Morsy, M. A., Ibrahim, S. A., Abdelwahab, S. A., Zedan, M. Z. & Elbitar, H. I. Curative effects of hydrogen sulfide against acetaminophen-induced hepatotoxicity in mice. *Life Sci.* **87**, 692–698 (2010).
112. Li, L. *et al.* Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. *FASEB J.* **19**, 1196–1198 (2005).
113. Norris, E. J. *et al.* Hydrogen sulfide modulates sinusoidal constriction and contributes to hepatic microcirculatory dysfunction during endotoxemia. *Am. J. Physiol. Gastrointest. Liver Physiol.* **304**, G1070–G1078 (2013).
114. Wu, L. *et al.* Pancreatic islet overproduction of H<sub>2</sub>S and suppressed insulin release in Zucker diabetic rats. *Lab. Invest.* **89**, 59–67 (2009).
115. Lipson, K. L., Fonseca, S. G. & Urano, F. Endoplasmic reticulum stress-induced apoptosis and auto-immunity in diabetes. *Curr. Mol. Med.* **6**, 71–77 (2006).
116. Yang, G., Yang, W., Wu, L. & Wang, R. H<sub>2</sub>S, endoplasmic reticulum stress, and apoptosis of insulin-secreting  $\beta$  cells. *J. Biol. Chem.* **282**, 16567–16576 (2007).
117. Jia, X. *et al.* The role of H<sub>2</sub>S in insulin resistance. *57th Annual Meeting of the Canadian Cardiovascular Congress* [online], <http://www.pulsus.com/ccc2004/abs/a041.htm> (2004).
118. Veldman, B. A., Vervoort, G., Blom, H. & Smits, P. Reduced plasma total homocysteine concentrations in type 1 diabetes mellitus is determined by increased renal clearance. *Diabet. Med.* **22**, 301–305 (2005).
119. Yusuf, M. *et al.* Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis. *Biochem. Biophys. Res. Commun.* **333**, 1146–1152 (2005).
120. Yang, G., Tang, G., Zhang, L., Wu, L. & Wang, R. The pathogenic role of cystathionine  $\gamma$ -lyase/hydrogen sulfide in streptozotocin-induced diabetes in mice. *Am. J. Pathol.* **179**, 869–879 (2011).
121. Whiteman, M. *et al.* Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulfide. *Diabetologia* **53**, 1722–1726 (2010).
122. Szabo, C. Roles of hydrogen sulfide in the pathogenesis of diabetes mellitus and its complications. *Antioxid. Redox Signal.* **17**, 68–80 (2012).
123. Suzuki, K. *et al.* Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. *Proc. Natl Acad. Sci. USA* **108**, 13829–13834 (2011). **This paper shows that endogenous or exogenous H<sub>2</sub>S can prevent hyperglycaemia-associated damage to the vascular endothelium, indicating the therapeutic potential of H<sub>2</sub>S in the prevention of diabetes-associated vasculopathy.**
124. Liu, F. *et al.* Hydrogen sulfide improves wound healing via restoration of endothelial progenitor cell functions and activation of angiotensin 1 in type 2 diabetes. *Diabetes* **63**, 1763–1778 (2014).
125. Zhong, X. *et al.* Exogenous hydrogen sulfide attenuates diabetic myocardial injury through cardiac mitochondrial protection. *Mol. Cell. Biochem.* **371**, 187–198 (2012).
126. Eto, K., Asada, T., Arima, K., Makifuchi, T. & Kimura, H. Brain hydrogen sulfide is severely decreased in Alzheimer's disease. *Biochem. Biophys. Res. Commun.* **293**, 1485–1488 (2002).
127. Tang, X. Q. *et al.* Effect of hydrogen sulfide on  $\beta$ -amyloid-induced damage in PC12 cells. *Clin. Exp. Pharmacol. Physiol.* **35**, 180–186 (2008).
128. Fan, H. *et al.* Hydrogen sulfide protects against amyloid  $\beta$ -peptide induced neuronal injury by attenuating inflammatory responses in a rat model. *J. Biomed. Res.* **27**, 296–304 (2013).
129. Xuan, A. *et al.* Hydrogen sulfide attenuates spatial memory impairment and hippocampal neuro-inflammation in  $\beta$ -amyloid rat model of Alzheimer's disease. *J. Neuroinflamm.* **9**, 202 (2012).
130. Zhang, L. M., Jiang, C. X. & Liu, D. W. Hydrogen sulfide attenuates neuronal injury induced by vascular dementia via inhibiting apoptosis in rats. *Neurochem. Res.* **34**, 1984–1992 (2009).
131. Hu, L. F. *et al.* Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. *Aging Cell* **9**, 135–146 (2010).
132. Kida, K. *et al.* Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease. *Antioxid. Redox Signal.* **15**, 343–352 (2011).
133. Campolo, M. *et al.* A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury. *FASEB J.* **27**, 4489–4499 (2013).
134. Distrutti, E. *et al.* 5-amino 2 hydroxybenzoic acid 4-[5 thioxo 5H-[1,2]dithiol 3yl]-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. *J. Pharmacol. Exp. Ther.* **319**, 447–458 (2006).
135. Matsunami, M. *et al.* Luminal hydrogen sulfide plays a pronociceptive role in mouse colon. *Gut* **58**, 751–771 (2009).
136. Ekundi-Valentim, E. *et al.* Differing effects of exogenous and endogenous hydrogen sulphide in carrageenan-induced knee joint synovitis in the rat. *Br. J. Pharmacol.* **159**, 1463–1474 (2010).
137. Donatti, A. F. *et al.* Role of hydrogen sulfide in the formalin-induced orofacial pain in rats. *Eur. J. Pharmacol.* **738**, 49–56 (2014).
138. Paquette, J. M. *et al.* Safety, tolerability and pharmacokinetics of trimebutine 3-thiobarbamoilbenzenesulfonate (GIC-1001) in a randomized Phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers. *Clin. Ther.* **36**, 1650–1664 (2014).
139. Fiorucci, S. *et al.* Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. *Gastroenterology* **129**, 1210–1224 (2005).
140. Wallace, J. L. Physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract. *Antioxid. Redox Signal.* **12**, 1125–1133 (2010).
141. Mard, S. A. *et al.* Gastroprotective effect of NaHS against mucosal lesions induced by ischemia-reperfusion injury in rat. *Dig. Dis. Sci.* **57**, 1496–1503 (2012).
142. Zanardo, R. C. *et al.* Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. *FASEB J.* **20**, 2118–2120 (2006). **This is the first demonstration of the potent anti-inflammatory effects of endogenous and exogenous H<sub>2</sub>S, including inhibition of leukocyte adherence to the vascular endothelium.**



143. Wallace, J. L., Keenan, C. M. & Granger, D. N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. *Am. J. Physiol.* **259**, G462–G467 (1990).
144. Blackler, R. W., Gemic, B., Manko, A. & Wallace, J. L. NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. *Curr. Opin. Pharmacol.* **19**, 11–16 (2014).
145. Takeuchi, K. *et al.* Gas mediators involved in modulating duodenal HCO<sub>3</sub> secretion. *Curr. Med. Chem.* **19**, 43–54 (2012).
146. Wallace, J. L., Caliendo, G., Santagada, V., Cirino, G. & Fiorucci, S. Gastrointestinal safety and anti-inflammatory effects of hydrogen sulfide-releasing diclofenac derivative in the rat. *Gastroenterology* **132**, 261–271 (2007).
147. Li, L. *et al.* Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. *Free Radic. Biol. Med.* **42**, 706–719 (2007).
148. Wallace, J. L., Caliendo, G., Santagada, V. & Cirino, G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). *Br. J. Pharmacol.* **159**, 1236–1246 (2010).
149. Blackler, R. *et al.* Gastrointestinal sparing effects of novel NSAIDs in rats with compromised mucosal defence. *PLoS ONE* **7**, e35196 (2012).
150. Wallace, J. L. Hydrogen sulfide-releasing anti-inflammatory drugs. *Trends Pharmacol. Sci.* **28**, 501–505 (2007).
151. Wallace, J. L., Ferraz, J. G. P. & Muscara, M. N. Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. *Antioxid. Redox Signal.* **17**, 58–67 (2012).
152. Wallace, J. L., Dickey, M., McKnight, W., Martin, G. R. Hydrogen sulfide enhances ulcer healing in rats. *FASEB J.* **21**, 4070–4076 (2007).
- This was the first study to highlight a critical role of H<sub>2</sub>S synthesis at sites of injury in driving repair *in vivo*, suggesting that H<sub>2</sub>S has important therapeutic potential.**
153. Zayachkivska, O. *et al.* Cytoprotective effects of hydrogen sulfide in novel rat models of non-erosive esophagitis. *PLoS ONE* **9**, e110688 (2014).
154. Wallace, J. L. Polypharmacy of osteoarthritis: the perfect intestinal storm. *Dig. Dis. Sci.* **58**, 3088–3093 (2013).
155. Blackler, R. W. *et al.* Hydrogen sulfide protects against NSAID-enteropathy through modulation of bile and the microbiota. *Br. J. Pharmacol.* <http://dx.doi.org/10.1111/bph.12961> (2014).
156. Flannigan, K. L., Ferraz, J. G. P., Wang, R. & Wallace, J. L. Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: a site-specific, pro-resolution mechanism. *PLoS ONE* **8**, e71962 (2013).
157. Fiorucci, S. *et al.* Enhanced activity of a hydrogen sulphide-releasing derivative of mesalazine (ATB-429) in a mouse model of colitis. *Br. J. Pharmacol.* **150**, 996–1002 (2007).
158. Flannigan, K. L. *et al.* Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-associated exacerbation of colitis. *Proc. Natl Acad. Sci. USA* **111**, 13559–13564 (2014).
159. Wang, J. & Hegele, R. A. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine  $\gamma$ -lyase (CTH). *Hum. Genet.* **112**, 404–408 (2003).
160. Zhu, W., Lin, A. & Banerjee, R. Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine  $\gamma$ -lyase. *Biochemistry* **47**, 6226–6232 (2008).
161. Banerjee, R. & Zou, C. G. Redox regulation and reaction mechanism of human cystathionine- $\beta$ -synthase: a PLP-dependent hemesensor protein. *Arch. Biochem. Biophys.* **433**, 144–156 (2005).
162. Ichinohe, A. *et al.* Cystathionine  $\beta$ -synthase is enriched in the brains of Down's patients. *Biochem. Biophys. Res. Commun.* **338**, 1547–1550 (2005).
163. Billaut-Laden, I. *et al.* Evidence for a functional genetic polymorphism of the human mercaptopyruvate sulfurtransferase (MPST), a cyanide detoxification enzyme. *Toxicol. Lett.* **165**, 101–111 (2006).
164. Blackstone, E., Morrison, M. & Roth, M. B. H<sub>2</sub>S induces a suspended animation-like state in mice. *Science* **308**, 515 (2005).
165. Szabo, C. Hydrogen sulfide and its therapeutic potential. *Nature Rev. Drug Discov.* **6**, 917–935 (2007).
166. Wallace, J. L. Mechanisms, prevention & clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. *World J. Gastroenterol.* **19**, 1861–1876 (2013).
167. Kearney, P. M. *et al.* Do selective cyclo-oxygenase 2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. *BMJ* **332**, 1302–1308 (2006).
168. Chattopadhyay, M., Kodala, R., Olson, K. R. & Kashfi, K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth *in vitro* and in a xenograft mouse model. *Biochem. Biophys. Res. Commun.* **419**, 523–528 (2012).
169. Kashfi, K. Anti-cancer activity of new designer hydrogen sulfide-donating hybrids. *Antioxid. Redox Signal.* **20**, 831–846 (2014).
170. Karabulut, G. S. *et al.* The incidence of irritable bowel syndrome in children using Rome III criteria and the effect of trimebutine treatment. *J. Neurogastroenterol. Motil.* **19**, 90–93 (2013).
171. Elrod, J. W. *et al.* Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. *Proc. Natl Acad. Sci. USA* **104**, 15560–15565 (2007).
- In this study, the potent cardioprotective effects of H<sub>2</sub>S were demonstrated in experimental myocardial infarction, and shown to be largely attributable to the preservation of myocardial mitochondrial function and reduced production of reactive oxygen species.**
172. Li, L. *et al.* Characterization of a novel, water soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. *Circulation* **117**, 2351–2360 (2008).
173. Li, L. *et al.* GYY4137, a novel hydrogen sulfide-releasing molecule, protects against endotoxic shock in the rat. *Free Radic. Biol. Med.* **47**, 103–113 (2009).
174. Li, L. *et al.* The complex effects of the slow-releasing hydrogen sulfide donor GYY4137 in a model of acute joint inflammation and in human cartilage cells. *J. Cell. Mol. Med.* **17**, 365–376 (2013).
175. Bucci, M. *et al.* Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition. *Cardiovasc. Res.* **102**, 128–147 (2014).
176. McCook, O. *et al.* H<sub>2</sub>S during circulatory shock: some unresolved questions. *Nitr. Oxide* <http://dx.doi.org/10.1016/j.niox.2014.03.163> (2014).
177. Olson, K. A practical look at the chemistry and biology of hydrogen sulfide. *Antiox. Redox Signal.* **17**, 32–44 (2012).
178. Shen, X., Peter, E. A., Bir, S., Wang, R. & Kevil, C. G. Analytical measurement of discrete hydrogen sulfide pools in biological specimens. *Free Radic. Biol. Med.* **52**, 2276–2283 (2012).
179. Peter, E. A. *et al.* Plasma-free H<sub>2</sub>S levels are elevated in patients with cardiovascular disease. *J. Am. Heart Assoc.* **2**, e000387 (2013).
180. Bos, E. M. *et al.* Cystathionine  $\gamma$ -lyase protects against renal ischemia/reperfusion by modulating oxidative stress. *J. Am. Soc. Nephrol.* **24**, 759–770 (2013).
181. Shirozu, K. *et al.* Cystathionine  $\gamma$ -lyase deficiency protects mice from galactosamine/lipopolysaccharide-induced acute liver failure. *Antioxid. Redox Signal.* **20**, 204–216 (2014).
182. Shen, X. *et al.* Microbial regulation of host hydrogen sulfide bioavailability and metabolism. *Free Radic. Biol. Med.* **60**, 195–200 (2013).
183. Flannigan, K. L., McCoy, K. D. & Wallace, J. L. Eukaryotic and prokaryotic contributions to colonic hydrogen sulfide synthesis. *Am. J. Physiol. Gastrointest. Liver Physiol.* **301**, G188–G193 (2011).
184. Mimoun, S. *et al.* Detoxification of H<sub>2</sub>S by differentiated colonic epithelial cells: implication of the sulfide oxidizing unit and of the cell respiratory capacity. *Antioxid. Redox Signal.* **17**, 1–10 (2012).
185. Motta, J. P. *et al.* Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. *Inflamm. Bowel Dis.* <http://dx.doi.org/10.1097/MIB.0000000000000345> (2015).
186. Rey, F. E. *et al.* Metabolic niche of a prominent sulfate-reducing human gut bacterium. *Proc. Natl Acad. Sci. USA* **110**, 13582–13587 (2013).
187. Berg, J. S. *et al.* Polysulfides as intermediates in the oxidation of sulfide to sulfate by *Beggiata* spp. *Appl. Environ. Microbiol.* **80**, 629–636 (2014).
188. Furne, J., Saeed, A. & Levitt, M. D. Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than present accepted values. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **295**, R1479–R1485 (2008).
189. Magee, E. A., Richardson, C. J., Hughes, R. & Cummings, J. H. Contribution of dietary protein to sulfide production in the large intestine: an *in vitro* and a controlled feeding study in humans. *Am. J. Clin. Nutr.* **72**, 1488–1494 (2000).
190. Roediger, W. E., Duncan, A., Kapaniris, O. & Millard, S. Sulphide impairment of substrate oxidation in rat colonocytes: a biochemical basis for ulcerative colitis? *Clin. Sci.* **85**, 623–627 (1993).
191. Attene-Ramos, M. S., Wagner, E. D., Plewa, M. J. & Gaskins, H. R. Evidence that hydrogen sulfide is a genotoxic agent. *Mol. Cancer Res.* **4**, 9–14 (2006).
192. Cao, Q. *et al.* Butyrate-stimulated H<sub>2</sub>S production in colon cancer cells. *Antioxid. Redox Signal.* **12**, 1101–1109 (2010).
193. Chan, M. V. & Wallace, J. L. Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. *Am. J. Physiol. Gastrointest. Liver Physiol.* **305**, G467–G473 (2013).

#### Acknowledgements

J.L.W. and R.W. are supported by grants from the Canadian Institutes of Health Research.

#### Competing interests statement

The authors declare **competing interests**: see Web version for details.

#### FURTHER INFORMATION

Antibe Therapeutics press release on ATB-346: [http://www.antibetherapeutics.com/PressReleases.asp?ReportID=6775316\\_Type=Press-Releases&Title=ANTIBE-THERAPEUTICS-COMPLETES-SINGLE-ASCENDING-DOSE-PORTION-OF-ATB-346-PHASE3-ClinicalTrials.gov](http://www.antibetherapeutics.com/PressReleases.asp?ReportID=6775316_Type=Press-Releases&Title=ANTIBE-THERAPEUTICS-COMPLETES-SINGLE-ASCENDING-DOSE-PORTION-OF-ATB-346-PHASE3-ClinicalTrials.gov): <http://clinicaltrials.gov/>

ALL LINKS ARE ACTIVE IN THE ONLINE PDF